| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | RNA-Based Therapies | Nervous System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | RNA-Based Therapies | Nervous System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | RNA-Based Therapies | Nervous System |
Recent Updates
Recently added Catalysts
Biogen Inc.$199.15
+0.24 (+0.12%)
A 89Pipeline Score Undervalued Biotech · Commercial
Market Cap
28.61 B
EPS
9.35
P/E Ratio
20.79 $
Value Trade
173.56 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.48 B
R&D Expenses
539.00 M
Operating CF
645.50 M
Total Assets
29.48 B
Total Liabilities
10.83 B
Equity
18.65 B
D/E Ratio
12,345
1.01 %
Week
2.35 %
1 Month
1.56 %
3 Month
14.96 %
6 Month
-32.16 %
5 Year
6,722.46 %
All Time
Cash Data
Cash Position
3.41 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 29, 2026
Overview
Volume
1.13 M
52 Week Range
121.05 - 205.97
% held by Insiders
0.89 %
% held by Institutions
99.68 %
Enterprise Value
30.89 B
Total Shares
147.68 M
Short %
3.88 %
Float Shares
147.39 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Biogen Inc.
610Total events
24Upcoming
279Tier-1 (high impact)
2009 – 2028Coverage
Upcoming catalysts 24
Jul 12, 2026
T2Oral Presentation
Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease: Emerging Clinical Evidence and Practical Use Considerations
Jul 13, 2026
T3Poster Presentation
Real-world Insights into Clinician Involvement and Testing Approaches for Mild Cognitive Impairment and Alzheimer's at AAIC 2026
Jul 14, 2026
T2Oral Presentation
Topline Results from CELIA: A Phase 2 Study to Evaluate the Tau-Targeting ASO Diranersen (BIIB080) in Patients with Early Alzheimer’s Disease
Jul 14, 2026
T2Oral Presentation
Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse U.S. Clinical Settings
Jul 15, 2026
T3Poster Presentation
Impact of Biomarker Modalities in Diagnostic Evaluation of Suspected Alzheimer's Disease at AAIC 2026
Aug 24, 2026
T1PDUFA Date
FDA extends review period for sBLA for lecanemab subcutaneous starting dose; new PDUFA date August 24, 2026
2027
T1Topline Readout
First data readout anticipated from TRANSCEND study in late antibody-mediated rejection
TBD
T2Oral Presentation
Detailed findings from LUMA study to be presented at an upcoming scientific conference
Event history 586
Q3 2026
◆Trial InitiationRayThera lead immunology candidateTrial
Lead candidate expected to enter Phase 1 development
immune-mediated conditionssource ↗
Jun 22, 2026
◆Poster PresentationFelzartamabPresentation
TRANSCEND and TRANSPIRE: phase 3 and 2 trials of the anti-CD38 antibody felzartamab in kidney transplant recipients with antibody medical rejection or isolated microvascular inflammation
Antibody mediated rejection or isolated microvascular inflammationsource ↗
Jun 21, 2026
◆Oral PresentationpegcetacoplanPresentation
Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex membranoproliferative Glomerulonephritis
Posttransplant C3G or primary IC-MPGNsource ↗
Jun 20, 2026
◆Poster PresentationPresentation
Establishing a central pathology review process and adjudication framework to standardize biopsy-based endpoints in transplant clinical trials
Transplant clinical trialssource ↗
Jun 5, 2026
◆Oral PresentationFelzartamabPresentation
Prolonged CD38 Targeting with Felzartamab Achieves Sustained Suppression of Antibody-mediated Rejection: Biomarker-guided Open-label Phase 2 Extension
Antibody-mediated rejection (AMR)source ↗
Jun 5, 2026
◆Poster PresentationpegcetacoplanPresentation
Pegcetacoplan population pharmacokinetics and exposure-response analysis in adolescent and adult patients with C3G or primary IC-MPGN
C3G or primary IC-MPGNsource ↗
Jun 4, 2026
▲Breakthrough Therapy DesignationSalanersenDesignation
FDA granted Breakthrough Therapy Designation for salanersen in SMA
spinal muscular atrophysource ↗
Jun 4, 2026
▲Poster Presentationdapirolizumab pegolPresentation
Poster presentation at EULAR 2026 showing steroid tapering and disease control data
systemic lupus erythematosussource ↗
Jun 4, 2026
▲Abstractdapirolizumab pegolPresentation
Abstract AB1163 on flare rates using alternative definitions
systemic lupus erythematosussource ↗
Jun 4, 2026
◆Oral PresentationpegcetacoplanPresentation
Pegcetacoplan treatment response in VALIANT/VALE: Impact of disease chronicity in C3G and primary IC-MPGN
C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN)source ↗
Jun 2026
◆Trial InitiationSalanersenTrial
Recruitment expected to begin for STELLAR-2 Phase 3 study
spinal muscular atrophysource ↗
Drug Pipeline Intelligence
A89
Pipeline Score $56.4B
Pipeline ValueUndervalued
Valuation Signal116
Drugs Scored6.6x
rNPV / MCap Top 99%
Mid Cap (rank 10 of 911)
Percentile RankBiogen Inc. earns an A-grade pipeline score (89/100), with $66.3B risk-adjusted pipeline value, led by Alefacept in Chronic Plaque Psoriasis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alefacept Small molecule | Chronic Plaque Psoriasis | Phase 3 | NCT00233662 | 64% | $5.5B | COMPLETED | 673 | - | - | Dec 1, 2005 | - | Aug 23, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
diranersen Fast Track | early Alzheimer’s disease | Phase 2 | 2026-06-29 | initial clinical, biomarker and safety results | Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen Read More | |
diranersen Fast Track | early Alzheimer’s disease | Phase 2 | 2026-06-29 | initial clinical, biomarker and safety results | Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen Read More | |
diranersen Fast Track | early Alzheimer’s disease | Phase 2 | 2026-06-29 | initial clinical, biomarker and safety results | Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BIIB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BIIB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BIIBBiogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
Biogen will present new data on its Alzheimer's disease portfolio at the AAIC 2026, including Phase 2 CELIA results for diranersen, a tau-targeting ASO. The conference will also feature emerging data on lecanemab, focusing on subcutaneous administration and real-world applications. This highlights Biogen's ongoing commitment to innovation in Alzheimer's care.
Read more →BIIBBiogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Biogen has announced its agreement to acquire RayThera Inc. for up to $1 billion, enhancing its immunology pipeline. The deal includes an upfront payment and contingent milestone payments based on clinical and regulatory achievements. RayThera's lead candidate is expected to enter Phase 1 development in early Q3 2026. The acquisition aims to expand Biogen's capabilities in treating immune-mediated conditions.
Read more →BIIBBiogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Biogen announced that the FDA has granted Breakthrough Therapy Designation for its investigational drug salanersen, intended for the treatment of spinal muscular atrophy (SMA). This designation is supported by exploratory data from a Phase 1b study, which showed meaningful clinical improvements in motor function among children previously treated with gene therapy. The drug, a novel antisense oligonucleotide, is designed for once-yearly administration. Biogen is now preparing for Phase 3 studies to further evaluate its safety and efficacy.
Read more →BIIBEULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
At EULAR 2026, data from the Phase 3 PHOENYCS GO study demonstrated that dapirolizumab pegol (DZP) significantly reduces flare rates and maintains disease control in systemic lupus erythematosus (SLE) patients. The study showed that patients on DZP could taper glucocorticoids while achieving sustained disease control. Additionally, improvements in immunological markers were reported, highlighting the potential of DZP in managing SLE effectively.
Read more →BIIBBiogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
Biogen has announced that fourteen abstracts from its nephrology portfolio, including EMPAVELI and felzartamab, will be presented at the upcoming European Renal Association Congress and American Transplant Congress. The presentations will showcase new data on the efficacy and safety of EMPAVELI in treating kidney diseases. This marks a significant step in Biogen's efforts to broaden its nephrology offerings.
Read more →BIIBUCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
UCB and Biogen announced the publication of positive results from the Phase 3 PHOENYCS GO study of dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE). The study demonstrated significant improvements in disease activity at Week 48 compared to placebo. The findings support the ongoing Phase 3 PHOENYCS FLY trial, which is currently recruiting patients.
Read more →BIIBBiogen Inc. (BIIB) Investors with Losses are Urged to Contact The Gross Law Firm to Discuss Their Rights
The Gross Law Firm is investigating potential securities fraud claims on behalf of investors in Biogen Inc. (BIIB) who may have experienced financial losses. This investigation stems from allegations of misleading statements that could have inflated the stock's value artificially. Investors who believe they have incurred losses are encouraged to contact the firm for potential recovery options.
Read more →BIIBBiogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Biogen and Denali Therapeutics announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints. As a result, they will discontinue its development for idiopathic Parkinson's disease. However, Denali will continue the Phase 2a BEACON study for a specific genetic variant related to LRRK2.
Read more →BIIB▼ -6.4%on this news
Biogen Completes Acquisition of Apellis Pharmaceuticals
Biogen has successfully completed its acquisition of Apellis Pharmaceuticals, enhancing its portfolio with two commercialized products, EMPAVELI and SYFOVRE. This acquisition is expected to significantly boost Biogen's revenue and EPS growth potential. Additionally, Apellis's established infrastructure will aid in the launch of felzartamab, targeting kidney transplant patients. Financial guidance will be updated in the upcoming Q2 earnings report.
Read more →BIIBCNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
The article discusses breakthroughs in CNS drug delivery, highlighting the challenges posed by the blood-brain barrier (BBB) and the innovative solutions being developed by companies like Oncotelic Therapeutics. As Alzheimer's disease cases rise, the need for effective drug delivery systems is becoming increasingly urgent. The article emphasizes the importance of platform-based solutions in overcoming these challenges and improving therapeutic outcomes.
Read more →BIIBUpdate on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
Eisai and Biogen announced an extension of the FDA review period for LEQEMBI IQLIK, a subcutaneous injection for early Alzheimer's disease, by three months to August 24, 2026. The FDA requested additional information, but has not expressed concerns about the drug's approvability. LEQEMBI has received approval from over 50 regulatory bodies globally, indicating strong confidence in its efficacy.
Read more →BIIB▲ +6%on this news
Document Press Release Cambridge, Mass.
Biogen reported strong financial results for the first quarter of 2026, with total revenue increasing 2% year-over-year to $2.5 billion. Key growth products such as LEQEMBI and ZURZUVAE demonstrated substantial revenue increases, significantly boosting the company's overall performance. However, SPINRAZA revenue saw a decline of 12% year-over-year, and the forecast for the full year indicates potential revenue challenges ahead. The planned acquisition of Apellis Pharmaceuticals is expected to enhance Biogen's portfolio and long-term growth prospects.
Read more →BIIBBiogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Biogen has entered an agreement to acquire exclusive rights to felzartamab in the Greater China Region from TJ Biopharma. This acquisition consolidates global rights for the drug, which is currently in Phase 3 trials for multiple immune-mediated diseases. The deal includes a $100 million upfront payment and potential milestone payments totaling up to $850 million. Biogen aims to leverage this opportunity to enhance its development portfolio in a key market.
Read more →BIIBBiogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Biogen has announced its acquisition of Apellis Pharmaceuticals for $5.6 billion, enhancing its portfolio with two FDA-approved immunology products, EMPAVELI and SYFOVRE. This acquisition is expected to significantly boost Biogen's revenue and growth prospects, particularly in nephrology. The deal includes a contingent value right tied to SYFOVRE's sales performance. Biogen anticipates the acquisition will be accretive to earnings starting in 2027.
Read more →BIIBTENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this " Agreement "), dated as of
Biogen Inc. has entered into a Tender and Support Agreement with stockholders concerning its planned acquisition of Apellis Pharmaceuticals, Inc. The agreement facilitates a tender offer for all outstanding shares of Apellis, leading to a merger. This strategic move is aimed at bolstering Biogen's portfolio as it seeks to enhance its market presence.
Read more →BIIBBiogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Biogen announced positive results from the Phase 2 AMETHYST study of litifilimab for cutaneous lupus erythematosus (CLE), showing significant reductions in disease activity. The trial met its primary endpoint, demonstrating an 11.8% higher reduction in skin disease activity compared to placebo. This therapy could potentially be the first new treatment for CLE in 70 years, addressing significant unmet needs.
Read more →BIIBFDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Biogen has received FDA approval for a High Dose Regimen of SPINRAZA (nusinersen) to treat spinal muscular atrophy (SMA). This regimen allows for an accelerated loading phase and is backed by data from the DEVOTE study, which showed significant motor function improvements in treatment-naïve infants. The High Dose SPINRAZA will be available in the U.S. and is also approved in the EU, Switzerland, and Japan.
Read more →BIIBResults from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Eisai and Biogen presented new findings on lecanemab's long-term treatment persistence at the AD/PD 2026 conference. The analysis revealed that 94% of patients who completed 18 months of treatment chose to continue in a long-term extension study. The study demonstrated that a significant proportion of patients maintained treatment for up to 24 months, indicating strong adherence and potential benefits in managing Alzheimer's disease.
Read more →BIIBBiogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Biogen has announced the presentation of late-breaking data from the Phase 2 AMETHYST study of litifilimab for cutaneous lupus erythematosus (CLE) at the 2026 American Academy of Dermatology Annual Meeting. The data demonstrates positive results supporting the safety and efficacy of litifilimab, which has recently received Breakthrough Therapy Designation from the FDA. This presentation is part of Biogen's commitment to developing innovative treatments for serious conditions like CLE, which currently lacks targeted therapies. Future developments in the AMETHYST study are expected, with Phase 3 results projected for 2027.
Read more →BIIBBiogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
Biogen has presented new Phase 1b data showing the promising safety and effectiveness of salanersen, an investigational antisense oligonucleotide for treating spinal muscular atrophy (SMA) in children previously treated with gene therapy. The data revealed that participants experienced significant improvements in motor function and neurodegeneration markers after receiving the treatment. Additionally, the company unveiled the design for upcoming Phase 3 clinical trials to further assess salanersen's efficacy across a broader SMA population.
Read more →BIIBBiogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
Biogen will present new data on spinal muscular atrophy (SMA) treatments at upcoming conferences, including high dose nusinersen and salanersen. The presentations will highlight long-term benefits of nusinersen and the potential of salanersen as a once-yearly treatment. The company is also advancing salanersen into Phase 3 studies, indicating ongoing commitment to SMA research.
Read more →BIIBBiogen Announces Board Chair Transition
Biogen Inc. announced the election of Dr. Maria C. Freire as the new Chair of the Board of Directors, succeeding Caroline Dorsa, who is retiring. Dr. Freire, a board member since 2021, is expected to guide Biogen through its next growth phase, leveraging her extensive background in biomedical innovation and public health. The transition is seen as crucial for the company's future, with several significant developments anticipated in the coming months.
Read more →BIIBBiologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
Eisai and Biogen announced that the Biologics License Application for the subcutaneous formulation of lecanemab has been designated for Priority Review by China's NMPA. This new formulation could allow patients to self-administer the treatment at home, enhancing convenience and potentially reducing healthcare costs. The approval process is expected to be expedited under the Priority Review procedure.
Read more →BIIBNature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
Biogen announced the publication of results from the Phase 2/3 DEVOTE study in Nature Medicine, showcasing the high-dose regimen of nusinersen for spinal muscular atrophy (SMA). The study demonstrated significant improvements in motor function among treatment-naïve infants. The high-dose regimen is under FDA review with a PDUFA action date of April 3, 2026.
Read more →BIIBBiogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
Biogen has received FDA Breakthrough Therapy Designation for litifilimab, a monoclonal antibody aimed at treating cutaneous lupus erythematosus (CLE), a chronic autoimmune skin disease with no targeted therapies. The designation underscores the urgent need for effective treatments for CLE, as current options primarily manage symptoms without altering disease progression. The ongoing Phase 3 AMETHYST study aims to further evaluate the efficacy and safety of litifilimab.
Read more →BIIBFDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
The FDA has accepted Eisai's Supplemental Biologics License Application for LEQEMBI IQLIK, a subcutaneous autoinjector for Alzheimer's treatment, under Priority Review. If approved, it would allow at-home administration, enhancing patient convenience. The action date is set for May 24, 2026, and the sBLA is supported by data showing safety and efficacy comparable to intravenous dosing.
Read more →BIIBBiogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Biogen has received European Commission approval for a high dose regimen of SPINRAZA (nusinersen) for treating spinal muscular atrophy (SMA). This new regimen, which includes higher doses and a more rapid loading phase, is based on positive results from the DEVOTE study, showing significant motor function improvements. The approval aims to enhance treatment options for SMA patients, with ongoing reviews in other regions, including the U.S.
Read more →BIIBBiologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China
Eisai and Biogen have announced that the Biologics License Application for the subcutaneous formulation of LEQEMBI (lecanemab) has been accepted by China's National Medical Products Administration. If approved, this treatment will allow patients to administer their doses at home, potentially improving access and reducing healthcare resource demands. This marks a significant step in Alzheimer's treatment options in China.
Read more →BIIBThe Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Read more →BIIBBiogen Issues Statement in Response to the Passing of Charles Weissmann, MD, Ph.D., Co-Founder of Biogen
Biogen Issues Statement in Response to the Passing of Charles Weissmann, MD, Ph.D., Co-Founder of Biogen
Read more →BIIB“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
Eisai and Biogen announced that LEQEMBI (lecanemab) has been included in China's Commercial Insurance Innovative Drug List, enhancing access to early Alzheimer's disease treatment. This list aims to bridge the coverage gap for innovative medicines. The initiative is set to take effect on January 1, 2026, following LEQEMBI's launch in China in June 2024.
Read more →BIIBBiogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Biogen and Stoke Therapeutics presented promising data on zorevunersen for Dravet syndrome at the 2025 AES Annual Meeting. Long-term studies showed significant seizure reductions and improvements in cognitive and behavioral outcomes. A propensity score analysis indicated zorevunersen's efficacy compared to standard treatments, supporting its potential as a disease-modifying therapy. Safety data also appeared favorable, with manageable adverse events.
Read more →BIIBEisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
Eisai and Biogen presented new data at the CTAD Conference 2025, highlighting the long-term benefits of LEQEMBI in delaying Alzheimer's disease progression. The findings indicate that early initiation of treatment can extend cognitive function for up to 8.3 years in patients with mild cognitive impairment. Additionally, a new subcutaneous formulation has shown comparable efficacy and safety to the intravenous version, enhancing patient convenience.
Read more →BIIBNew Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Eisai and Biogen presented new data at the CTAD Conference 2025 confirming the pharmacological effect of lecanemab on neurotoxic Aβ protofibrils in cerebrospinal fluid. The findings from a Phase III study indicate that lecanemab significantly binds to protofibrils and may slow the progression of Alzheimer's disease. The results highlight lecanemab's unique dual action on both protofibrils and amyloid plaques.
Read more →BIIBBiogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Biogen and Stoke Therapeutics will present data on zorevunersen at the 2025 American Epilepsy Society Annual Meeting. Zorevunersen is an investigational treatment for Dravet syndrome, demonstrating significant effects on seizure frequency and cognitive improvements. The data includes four years of clinical findings and new analyses from ongoing studies, highlighting its potential as a first-in-class therapy.
Read more →BIIBEisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
Eisai has filed a new drug application for a subcutaneous formulation of LEQEMBI in Japan, aiming to provide a more convenient treatment option for early Alzheimer's disease. This formulation allows for weekly home administration, maintaining efficacy and safety similar to intravenous methods. The application is based on positive results from Phase 3 studies.
Read more →BIIBEisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
Eisai has finalized the rolling submission of a Supplemental Biologics License Application for LEQEMBI IQLIK, a subcutaneous autoinjector for early Alzheimer's disease. This submission follows the FDA's Fast Track designation and is supported by data showing the efficacy and safety of subcutaneous administration. If approved, this option could enhance patient convenience and reduce healthcare resource demands.
Read more →BIIBBiogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Biogen and Dayra Therapeutics have entered a research collaboration to develop oral macrocyclic peptides targeting immunological conditions. This partnership aims to leverage Dayra's discovery platform to create effective treatments that could compete with existing antibody therapies. Biogen will fund the collaboration with a $50 million upfront payment and has options for further payments based on development milestones.
Read more →BIIBBiogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
Biogen will present new data on lecanemab at the upcoming CTAD Conference, focusing on subcutaneous administration and long-term treatment benefits. The company will also share insights on BIIB080, an investigational therapy targeting tau protein in Alzheimer's disease. These presentations aim to enhance treatment options and understanding of Alzheimer's progression.
Read more →BIIBBiogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Biogen and Stoke Therapeutics published findings from the BUTTERFLY study, revealing that children with Dravet syndrome face significant cognitive and behavioral impairments despite receiving standard anti-seizure medications. The study underscores the need for new therapies targeting the genetic causes of the condition. The data serves as a critical baseline for future treatment evaluations.
Read more →BIIBHigh Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Read more →BIIBBiogen Completes Acquisition of Alcyone Therapeutics
Biogen Inc. has completed the acquisition of Alcyone Therapeutics, a company known for its innovative drug delivery solutions. The focal point of this acquisition is the ThecaFlex DRx™ system, designed to replace traditional lumbar punctures in administering treatments, particularly for spinal muscular atrophy. While the technology has potential benefits, including enhancing patient accessibility, it is still undergoing clinical trials and awaits regulatory approvals. Biogen anticipates introducing the system for SPINRAZA in early 2028, contingent on successful trial outcomes.
Read more →BIIB“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
Read more →BIIBBiogen to Participate in Upcoming Investor Conferences
Biogen to Participate in Upcoming Investor Conferences
Read more →BIIBBiogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
Biogen will present new data on felzartamab, an investigational anti-CD38 monoclonal antibody, at the ASN Kidney Week 2025. The company is conducting three pivotal Phase 3 studies for various kidney indications, with the first data readout expected in 2027. Presentations will include findings on gene expression and vaccine immunity in patients with IgA nephropathy.
Read more →BIIBBiogen Reports Third Quarter 2025 Results
Biogen Reports Third Quarter 2025 Results
Read more →BIIBBiogen to Report Third Quarter 2025 Financial Results October 30, 2025
Biogen to Report Third Quarter 2025 Financial Results October 30, 2025
Read more →BIIBHealth Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease
Health Canada has granted authorization for LEQEMBI (lecanemab) to treat early Alzheimer's disease in specific patient populations. This approval is based on the successful Phase 3 Clarity AD study, which demonstrated significant efficacy in slowing cognitive decline. LEQEMBI is the first treatment targeting the underlying cause of Alzheimer's and is already approved in 51 countries.
Read more →BIIBBiogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
Biogen has entered into a licensing agreement with Vanqua Bio for exclusive rights to a preclinical oral C5aR1 antagonist. This addition aims to enhance Biogen's immunology portfolio, targeting inflammatory disorders with high unmet needs. The agreement includes a $70 million upfront payment and potential milestone payments totaling up to $990 million. Biogen plans to file an IND by 2027 if preclinical results remain positive.
Read more →BIIBBiogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
Biogen announced that it will present additional results from the Phase 3 study of dapirolizumab pegol (DZP) for systemic lupus erythematosus (SLE) at ACR Convergence 2025. The data will highlight efficacy across various endpoints, including disease activity and quality of life. DZP is one of the few biologics to report positive Phase 3 data in SLE.
Read more →BIIBLEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
Eisai and Biogen announced that their product, LEQEMBI IQLIK, has been named one of TIME's 'Best Inventions of 2025' in the Medical and Healthcare category. This subcutaneous autoinjector for Alzheimer's treatment allows patients to administer their medication at home, potentially streamlining the treatment process. The product was launched in October 2025, following its approval in August 2025.
Read more →BIIBBiogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Biogen and Stoke Therapeutics presented promising long-term data on zorevunersen at the 54th CNS Annual Meeting, indicating significant improvements in cognition and behavior in Dravet syndrome patients over two years. The open-label extension studies showed that 95% of patients reported better overall clinical status. However, some patients experienced treatment-emergent adverse events, including elevated CSF protein levels.
Read more →BIIBEisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
Eisai and Biogen have announced the U.S. launch of LEQEMBI IQLIK, a subcutaneous injection for Alzheimer's disease maintenance therapy after initial intravenous treatment. This new option allows patients to self-administer the medication at home, enhancing convenience and potentially reducing healthcare resource needs. The companies also introduced the LEQEMBI Companion program to support patients throughout their treatment journey.
Read more →BIIB“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
Eisai and Biogen announced the approval of LEQEMBI (lecanemab) for intravenous maintenance dosing in China. This treatment is aimed at patients with early Alzheimer's disease, following an initial dosing phase. LEQEMBI uniquely targets both amyloid plaques and tau tangles, addressing neurodegeneration in Alzheimer's. The approval is significant given the rising number of Alzheimer's patients in China.
Read more →BIIBLEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
Eisai and Biogen announced that Australia's Therapeutic Goods Administration has approved LEQEMBI (lecanemab) for treating mild cognitive impairment and mild dementia due to Alzheimer's disease. This decision follows a review process after an earlier denial by the TGA. The approval is significant given the rising number of dementia cases in Australia, projected to reach 1.1 million by 2065.
Read more →BIIBBiogen Provides Regulatory Update on High Dose Regimen of Nusinersen
Biogen announced that the FDA issued a Complete Response Letter for its supplemental New Drug Application for a high dose regimen of nusinersen, used to treat spinal muscular atrophy. The FDA's letter requested additional technical information but did not cite any clinical data deficiencies. Biogen plans to promptly resubmit the application based on available information.
Read more →BIIBBiogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
Biogen Inc. has announced its acquisition of Alcyone Therapeutics to enhance its drug delivery portfolio, specifically through ThecaFlex DRx™, an innovative device for antisense oligonucleotide therapies. This system promises to streamline medication administration for patients with neurological disorders, potentially eliminating the need for repeated lumbar punctures. The acquisition is seen as a strategic move to strengthen Biogen's capabilities in drug-device combinations and improve patient-centered solutions. Alcyone's team will be integrated into Biogen, while their other therapeutic assets will transition to a new company, Neela Therapeutics.
Read more →BIIBBiogen Receives European Commission Approval for ZURZUVAE (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Biogen has received European Commission approval for ZURZUVAE (zuranolone), marking it as the first treatment specifically approved for postpartum depression (PPD) in Europe. This innovative oral treatment is to be taken over 14 days and has shown rapid symptom relief in trials. The rollout aims to address significant unmet needs among women suffering from PPD, a condition that affects up to 20% of new mothers. Despite the optimism surrounding this approval, challenges remain in ensuring equitable access and managing potential side effects.
Read more →BIIBBiogen Highlights Multiple Assets and Indications in Lupus
Biogen Highlights Multiple Assets and Indications in Lupus
Read more →BIIB▲ +5.6%on this newsshared move
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
Biogen and Stoke Therapeutics have presented encouraging data on zorevunersen at the 36th International Epilepsy Congress, indicating its potential as the first disease-modifying treatment for Dravet syndrome. Results from Phase 1/2a and open-label extension studies show significant and durable reductions in seizures, along with improvements in cognition and quality of life. The drug has been generally well tolerated, and ongoing Phase 3 studies aim to further evaluate its efficacy and safety. The findings reinforce the investigational therapy's promise in treating this challenging condition.
Read more →BIIB▲ +5.6%on this newsshared move
Biogen to Participate in Upcoming Healthcare Conferences
Biogen to Participate in Upcoming Healthcare Conferences
Read more →BIIBFDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Read more →BIIBAustria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
Read more →BIIBBiogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
Read more →BIIBBIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Biogen Inc. on behalf of long-term stockholders following a class action complaint filed against the company for allegedly making false and misleading statements regarding its business practices and compliance controls. The investigation centers on claims that Biogen overestimated its governance and product efficacy, creating legal and financial risks. This news coincides with Biogen's recent stock price declines attributed to missed financial targets and challenges with product launches. On recent disclosures, Biogen also faced a subpoena from the Department of Justice concerning its foreign business operations.
Read more →BIIBBiogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
Biogen and Stoke Therapeutics have dosed the first patient in a Phase 3 clinical trial, EMPEROR, for zorevunersen, aimed at treating Dravet syndrome. This pivotal study will assess the efficacy and safety of this investigational treatment compared to a sham over a 52-week period. Dravet syndrome is characterized by severe seizures and cognitive impairments, with no existing treatments targeting its underlying causes. If successful, zorevunersen could represent a significant advancement in the way this disease is managed, potentially improving outcomes for affected patients.
Read more →BIIBBiogen to Report Second Quarter 2025 Financial Results July 31, 2025
Biogen to Report Second Quarter 2025 Financial Results July 31, 2025
Read more →BIIBBiogen Reports Second Quarter 2025 Results
Biogen Reports Second Quarter 2025 Results
Read more →BIIBTwo-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
Read more →BIIBNew Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease
New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease
Read more →BIIBBiogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary
Biogen has announced a significant $2 billion investment aimed at expanding its manufacturing capabilities in North Carolina’s Research Triangle Park as part of its 30th anniversary. This move enhances the company’s manufacturing infrastructure, which has already seen approximately $10 billion in investments since its establishment in the region. The new funds will focus on advancing antisense oligonucleotide capabilities and modernizing manufacturing through automation and AI, ensuring a resilient supply of innovative treatments. The company emphasizes its commitment to supporting the local workforce and continuing its operations at its largest manufacturing footprint in the United States.
Read more →BIIBBiogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
Biogen Inc. has announced its participation in the 2025 Alzheimer’s Association International Conference (AAIC) taking place July 27-31 in Toronto, Canada. The company will present important findings related to lecanemab (LEQEMBI) including 48-month data from the Clarity AD study, insights into a subcutaneous formulation, and updates from the Phase 2 trial of BIIB080, an investigational therapy. Biogen aims to improve treatment options for Alzheimer’s disease by sharing research on tau-targeted therapies and biomarkers. Educational initiatives will further promote understanding of Alzheimer's pathology.
Read more →BIIBBiogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
Biogen and Stoke Therapeutics presented data on zorevunersen at the 16th EPNS Congress, showing significant improvements in cognition and behavior for patients with Dravet syndrome after 68 weeks of treatment. The new data support its use as a potential first-in-class disease-modifying therapy and inform the design of the Phase 3 EMPEROR study. Zorevunersen addresses the underlying causes of Dravet syndrome, a severe condition with currently no approved treatment targeting cognitive and behavioral symptoms.
Read more →BIIBBiogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Read more →BIIBBiogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Read more →BIIBBiogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Read more →BIIBDapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Read more →BIIBBiogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs in Rare Kidney Diseases
Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs in Rare Kidney Diseases
Read more →BIIBBiogen to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Biogen to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Read more →BIIBBiogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
Biogen Inc. has partnered with City Therapeutics to develop novel RNA interference (RNAi) therapies, marking a strategic collaboration that combines their respective expertise. The agreement includes a $46 million payment to City Therapeutics, which encompasses an upfront payment and an investment in the company. The focus will initially be on advancing a therapy targeting central nervous system diseases. This partnership allows Biogen to enhance its research capabilities while potentially generating significant milestone payments through successful development.
Read more →BIIBEuropean Commission Grants Marketing Authorization for Leqembi® (lecanemab)
European Commission Grants Marketing Authorization for Leqembi® (lecanemab)
Read more →BIIBUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
Read more →BIIBBiogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
Read more →BIIBBiogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
Read more →BIIBBiogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Read more →BIIBBiogen to Participate in the Stifel 2025 Virtual CNS Forum
Biogen to Participate in the Stifel 2025 Virtual CNS Forum
Read more →BIIBEisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
Read more →BIIBThe Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease
Read more →BIIBBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Biogen and Stoke Therapeutics have entered a collaboration to develop zorevunersen, aimed at treating Dravet syndrome, a severe genetic epilepsy. Stoke retains exclusive rights in the U.S., Canada, and Mexico, while Biogen will handle commercialization in the rest of the world. The pivotal Phase 3 EMPEROR study is set to begin in Q2 2025, with results expected in late 2027. Zorevunersen has received FDA Breakthrough Therapy Designation, suggesting it may offer substantial improvements over existing treatments.
Read more →BIIBBiogen Reports Fourth Quarter and Full Year 2024 Results
Biogen Reports Fourth Quarter and Full Year 2024 Results
Read more →BIIBUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Read more →BIIBFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Read more →BIIBBIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS FEBRUARY 12, 2025
BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS FEBRUARY 12, 2025
Read more →BIIBBiogen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Biogen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Read more →BIIBBiogen Appoints Tim Power as Head of Investor Relations
Biogen Appoints Tim Power as Head of Investor Relations
Read more →BIIB“LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico
Read more →BIIBBiogen to Participate in the 7th Annual Evercore HealthCONx Conference
Biogen to Participate in the 7th Annual Evercore HealthCONx Conference
Read more →BIIBSamsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
Read more →BIIBEisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
Read more →BIIBEisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
Read more →BIIBBiogen to Report Third Quarter 2024 Financial Results October 30, 2024
Biogen to Report Third Quarter 2024 Financial Results October 30, 2024
Read more →BIIBBiogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
Read more →BIIBBiogen Appoints Daniel Quirk, MD, as Chief Medical Officer
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
Read more →BIIBMichael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 Robin Kramer, Chief Accounting Officer, to Succeed Him
Michael McDonnell, the Executive Vice President and Chief Financial Officer of Biogen, will retire in February 2025. Robin Kramer, the current Chief Accounting Officer, has been named as his successor. McDonnell has played a significant role in guiding Biogen towards sustainable growth and optimizing its financial structure. Kramer, who joined Biogen in 2018 with prior experience in various industries, will work alongside McDonnell to ensure a seamless transition.
Read more →BIIBBiogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
Read more →BIIBBiogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
Biogen Inc. has announced it will present new data related to its Alzheimer's portfolio at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) annual conference in Madrid, Spain. The presentations, scheduled from October 29 to November 1, will cover various aspects of Alzheimer's treatment and include insights on preclinical disease and disparities in research. The company emphasizes its ongoing commitment to innovation in treatment and research for Alzheimer's disease, which affects millions of people.
Read more →BIIBBiogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
Biogen Inc. will present new data regarding its investigational drug felzartamab at the American Society of Nephrology’s Kidney Week 2024. The late-breaking oral presentation will feature final results from the Phase 2 IGNAZ study focused on IgA nephropathy. Additionally, a second oral presentation will examine the effects of felzartamab on key biomarkers associated with IgAN. The company plans to advance felzartamab into Phase 3 studies, enhancing its commitment to addressing rare immune-mediated diseases.
Read more →BIIBBiogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
Read more →BIIBNew Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
Read more →BIIBBiogen Board Appoints Two New Independent Directors
Biogen Inc. has appointed two new independent directors to its Board of Directors: Dr. Lloyd B. Minor, effective October 1, 2024, and Prof. Sir Menelas Pangalos, effective January 1, 2025. Both directors bring extensive experience in research and development within the biopharmaceutical sector. Dr. Minor is currently Dean of Stanford University School of Medicine, while Prof. Pangalos previously served as Executive Vice President of Biopharmaceuticals R&D at AstraZeneca. Their appointments are expected to contribute positively to Biogen's ongoing efforts for sustainable growth and enhanced product portfolio.
Read more →BIIBBiogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
Biogen has announced positive topline results from the Phase 2/3 DEVOTE study of a higher dose regimen of nusinersen, aimed at treating spinal muscular atrophy (SMA) in infants. This investigational regimen demonstrated statistically significant improvements in motor function compared to a matched sham control group. The study's results indicated that the higher dose could lead to faster neurodegeneration slowing and meaningful clinical benefits. Biogen plans to submit for regulatory approval based on these findings.
Read more →BIIBBiogen to Report Second Quarter 2024 Financial Results August 1, 2024
Biogen to Report Second Quarter 2024 Financial Results August 1, 2024
Read more →BIIBBiogen Reports Second Quarter 2024 Results
Biogen Reports Second Quarter 2024 Results
Read more →BIIBNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024
Read more →BIIBBiogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
Biogen, Beckman Coulter, and Fujirebio have announced a collaboration to develop blood-based biomarkers for tau pathology in Alzheimer's disease. This partnership aims to create diagnostic tools that could enhance patient stratification and monitor treatment responses for future tau-targeting therapies. Biogen will contribute clinical study data while its partners will focus on the diagnostics and commercialization of these new tests. The initiative is expected to address unmet needs in blood-based biomarkers and aid in the development of disease-modifying therapies.
Read more →BIIBSage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
Read more →BIIBBIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER ALERT: Only 7 Days Remain For Investors To Move For Lead Plaintiff in Biogen Inc.
Biogen Inc. is under scrutiny with a securities class action lawsuit alleging that the company overstated its efforts in transparency and corporate governance from February 3, 2022, to February 13, 2024. Shareholders have a limited timeline of only seven days to file for lead plaintiff status, which ends on July 22, 2024. This lawsuit poses potential financial consequences for Biogen and its investors, with no upfront costs for those wishing to participate in the litigation. Bernstein Liebhard LLP, the law firm handling the case, has a notable track record in recovering substantial amounts for clients.
Read more →BIIB“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong
Read more →BIIBBiogen Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
The Portnoy Law Firm has initiated a class action lawsuit on behalf of investors in Biogen Inc. (NASDAQ: BIIB) who have experienced significant financial losses. This lawsuit stems from allegations that Biogen misled investors about its transparency, compliance controls, and the strength of its product portfolio. The situation escalated following a series of disclosures that prompted sharp declines in the company's stock price, particularly after the company revised its fiscal guidance downwards. Subsequent legal scrutiny from the DOJ adds further complications to Biogen's standing.
Read more →BIIBBIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
Biogen Inc. is facing a class action lawsuit for alleged securities violations related to the company's disclosures during the Class Period from February 3, 2022 to February 13, 2024. The lawsuit alleges that Biogen overstated its transparency and compliance controls, and that inadequate measures were in place, leading to potential legal repercussions from authorities. Following the announcement of a subpoena from the DOJ, Biogen's stock price fell sharply, indicating market concern over these developments.
Read more →BIIBBiogen Completes Acquisition of Human Immunology Biosciences
Biogen Inc. has completed its acquisition of Human Immunology Biosciences (HI-Bio), focusing on therapies for severe immune-mediated diseases. This acquisition enhances Biogen’s immunology portfolio by integrating felzartamab, an investigational therapeutic that has shown promising results in Phase 2 studies. Biogen plans to advance felzartamab to Phase 3 trials while working alongside HI-Bio to address unmet medical needs in patients with rare diseases. The collaboration aims to leverage both companies' expertise to improve patient outcomes in complex conditions.
Read more →BIIB“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
Read more →BIIBBiogen Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights – BIIB
Biogen Inc. is facing a class action lawsuit alleging securities law violations from shareholders who purchased stock between February 3, 2022, and February 13, 2024. The allegations include that Biogen made misleading statements regarding its compliance controls and overstated the strength of its Alzheimer's drug portfolio. The lawsuit claims these misrepresentations have subjected the company to legal and regulatory risks, alongside potential reputational damage. Shareholders interested in participating in the lawsuit have until July 22, 2024, to register.
Read more →BIIBBIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
Bernstein Liebhard LLP has announced the filing of a securities class action lawsuit against Biogen Inc., alleging violations of the Securities Exchange Act related to business operations and compliance issues. The lawsuit covers investors who purchased Biogen's securities between February 3, 2022, and February 13, 2024. The complaint claims that Biogen overstated its governance and compliance efforts and failed to disclose significant challenges impacting its Alzheimer’s disease product portfolio. Following these revelations, Biogen’s stock experienced a decline, reflecting investor concerns.
Read more →BIIBBIOGEN STOCK NOTICE: Lose Money on your Biogen Inc. (Nasdaq: BIIB) Investment? BFA Law Encourages You to Contact the Firm before July 22, 2024 Court Deadline
Bleichmar Fonti & Auld LLP has announced a deadline of July 22, 2024, for shareholders of Biogen Inc. to address their potential claims in a securities class action lawsuit. The lawsuit alleges that Biogen made materially false statements concerning its compliance with securities laws, the success of its Alzheimer's treatment Leqembi, and implications of its acquisition of Reata Pharmaceuticals. Investors saw a substantial drop in Biogen's stock price after the disclosures regarding these claims. Affected investors are encouraged to contact the law firm for guidance on their rights.
Read more →BIIBBIOGEN LEGAL DEADLINE: If You Lost Money on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Encouraged to Contact BFA Law Before July 2024 Court Deadline
Biogen Inc. is facing a securities class action lawsuit related to alleged violations of federal securities laws. The complaint claims Biogen made misleading statements concerning its compliance controls, the success of its Alzheimer’s treatment Leqembi, and the impacts of an acquisition of Reata Pharmaceuticals. The stock price reportedly declined as investors learned about these issues. A legal deadline to join the lawsuit has been set for July 22, 2024.
Read more →BIIBBIOGEN NOTICE: If You Suffered Losses on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to Contact BFA Law Before Approaching July 2024 Legal Deadline
Biogen Inc. is facing a securities class action lawsuit filed on May 22, 2024, alleging that the company made materially false statements regarding its compliance controls and the launch of its Alzheimer's treatment, Leqembi. The lawsuit also claims that Biogen's acquisition of Reata Pharmaceuticals was misrepresented. Following these allegations, Biogen's stock price experienced a significant decline. Investors who suffered losses are reminded to contact BFA Law before the upcoming legal deadline of July 22, 2024.
Read more →BIIBBiogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm
Biogen Inc. is facing a securities class action lawsuit filed in the U.S. District Court for the District of Colorado, alleging violations of federal securities laws. The lawsuit claims that Biogen made misleading statements regarding its business operations and compliance policies, which resulted in substantial losses for investors. The truth emerged as Biogen revised its earnings guidance and disclosed a subpoena from the DOJ, indicating legal troubles related to its international business practices. Investors are encouraged to seek legal representation to recover losses incurred.
Read more →BIIBFDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Read more →BIIBBIOGEN CASE DEADLINE: Biogen Inc. (Nasdaq: BIIB) Investors are Reminded of Upcoming July 2024 Legal Deadline and Encouraged to Contact BFA Law
Biogen Inc. is facing a securities class action lawsuit, with a deadline for investor claims set for July 22, 2024. The lawsuit alleges that the company engaged in unlawful conduct and made misleading statements about its compliance control effectiveness, the success of its Alzheimer's treatment Leqembi, and the impact of its acquisition of Reata Pharmaceuticals. Investors are encouraged to seek legal counsel if they suffered losses, as the law firm Bleichmar Fonti & Auld LLP is promoting the case.
Read more →BIIBBiogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel
Biogen Inc. (Nasdaq: BIIB) and Delta Flight Products (DFP) have announced a collaboration aimed at enhancing air travel accessibility for passengers with reduced mobility. They will engage with the community, particularly individuals with rare neuromuscular diseases, to gather insights on their travel experiences and specific needs. The partnership will debut its first initiative at the Cure SMA Annual Conference in June 2024, showcasing a prototype seat that allows wheelchair users to remain in their wheelchairs during flights. The collaboration aims to inform future innovations in air travel accessibility.
Read more →BIIBBIOGEN 50 DAY NOTICE: Investors of Biogen Inc. (Nasdaq: BIIB) are Encouraged to Contact BFA Law Before July 2024 Deadline in Securities Fraud Class Action
Biogen Inc. is facing a securities class action lawsuit with a deadline for investors to join by July 22, 2024. The lawsuit, announced by law firm Bleichmar Fonti & Auld LLP, alleges that Biogen made materially false statements about its compliance, the success of its Alzheimer's treatment Leqembi, and the effects of its acquisition of Reata Pharmaceuticals. Following these revelations, Biogen's stock price reportedly dropped significantly, prompting the firm to reach out to affected investors for potential compensation.
Read more →BIIBBIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against Biogen Inc. by Bragar Eagel & Squire, P.C., covering the period from February 3, 2022, to February 13, 2024. The lawsuit alleges that Biogen provided false and misleading statements about its corporate governance and operations. Recent financial results and strategic decisions, including the discontinuation of Aduhelm, have negatively impacted the company's stock price. The lawsuit emerges alongside ongoing regulatory scrutiny following previous controversies surrounding the company’s business practices.
Read more →BIIBBiogen Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – BIIB
Biogen Inc. is currently facing a class action lawsuit filed by Levi & Korsinsky LLP on behalf of investors alleging securities law violations. The lawsuit claims that Biogen misrepresented its transparency initiatives, compliance controls, and the performance of its Alzheimer’s product portfolio. The allegations also suggest that the company may have engaged in improper conduct in foreign operations, exposing it to regulatory scrutiny. Investors who suffered losses between February 3, 2022, and February 13, 2024, have the opportunity to request lead plaintiff status in the case.
Read more →BIIBBiogen to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Biogen to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Read more →BIIBBiogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
Read more →BIIBBIOGEN ALERT: BFA Law Announces Biogen Inc. (Nasdaq: BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact the Firm if You Suffered Losses
Biogen Inc. (Nasdaq: BIIB) has been sued for securities fraud, with the lawsuit stemming from alleged false statements made between February 2022 and February 2024. Accusations include misleading claims about the company's compliance procedures and the success of its Alzheimer's treatment, Leqembi, as well as the expected impact of its acquisition of Reata Pharmaceuticals. Following these revelations, Biogen has experienced a significant drop in stock price. Investors are encouraged to contact Bleistmar Fonti & Auld LLP for assistance regarding potential losses.
Read more →BIIBBiogen Inc. (Nasdaq: BIIB) Investors Notice: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
A class action lawsuit has been filed against Biogen Inc. on behalf of investors who acquired its securities between February 3, 2022, and February 13, 2024. The lawsuit alleges that Biogen made materially false and misleading statements regarding its compliance controls, the effectiveness of its Alzheimer's treatment Leqembi, and the impact of its acquisition of Reata Pharmaceuticals. The Portnoy Law Firm is offering complimentary case evaluations for affected investors seeking to recover losses incurred during this period.
Read more →BIIBBIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against Biogen Inc. for allegedly providing misleading information to investors during the specified Class Period. The suit specifically cites Biogen's operational and compliance shortcomings that could impact financial outcomes. The company has faced increasing scrutiny following past controversies regarding Aduhelm's approval and subsequent regulatory investigations. Following recent financial disclosures indicating underperformance, Biogen's stock experienced significant declines amid growing investor concerns.
Read more →BIIBBiogen to Participate in the Jefferies Global Healthcare Conference
Biogen to Participate in the Jefferies Global Healthcare Conference
Read more →BIIBBiogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
Biogen has announced a definitive agreement to acquire Human Immunology Biosciences for $1.15 billion plus potential milestones. This acquisition includes felzartamab, an investigational anti-CD38 monoclonal antibody that has shown promise in treating various immune-mediated diseases. Biogen plans to integrate HI-Bio's expertise and maintain a focus on advancing treatments for rare immune diseases. The transaction is subject to customary closing conditions and regulatory approvals, with a target completion in the third quarter of 2024.
Read more →BIIBBiogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Biogen and Ionis Pharmaceuticals announced the discontinuation of BIIB105, an investigational drug for amyotrophic lateral sclerosis, following the Phase 1/2 ALSpire study's topline results. While BIIB105 reduced ATXN2 protein levels, it failed to lower plasma neurofilament light chain, an important neurodegeneration marker, and did not show improvements in clinical outcomes. Adverse events leading to discontinuation were more frequent in patients receiving BIIB105. The companies remain committed to ALS research and will continue analyzing the study data.
Read more →BIIBEisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
Read more →BIIBBiogen Reports Progress on Corporate Responsibility Priorities
Biogen Reports Progress on Corporate Responsibility Priorities
Read more →BIIBBiogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA
Biogen has received a positive opinion from the CHMP for TOFIDENCE™ (tocilizumab), a biosimilar referencing ROACTEMRA, intended for treating various conditions, including rheumatoid arthritis and COVID-19. The opinion is based on comprehensive comparative data demonstrating equivalence to the reference product. The decision will now be reviewed by the European Commission for marketing authorization. This recommendation underscores Biogen's commitment to providing high-quality treatment options within Europe.
Read more →BIIBBiogen Reports First Quarter 2024 Results
Biogen Reports First Quarter 2024 Results
Read more →BIIBBIOGEN TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS APRIL 24, 2024
BIOGEN TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS APRIL 24, 2024
Read more →BIIBUpdate on European Medicines Agency Review of Lecanemab Marketing Authorization Application
Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application
Read more →BIIBEisai to Host Annual Information Meeting with Update on LEQEMBI® (lecanemab-irmb)
Eisai to Host Annual Information Meeting with Update on LEQEMBI® (lecanemab-irmb)
Read more →BIIBBiogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
Biogen Inc. is set to showcase new data regarding its Alzheimer's disease portfolio at the upcoming AD/PD 2024 conference in Lisbon, Portugal. Key presentations will include findings from the BIIB113 small molecule inhibitor and insights into tau aggregation. The company emphasizes its commitment to explore multiple treatment modalities aimed at transforming Alzheimer's care. However, the article also notes that the outcomes of ongoing clinical trials may not guarantee success in later stages.
Read more →BIIBBiogen to Participate in the TD Cowen 44th Annual Health Care Conference
Biogen to Participate in the TD Cowen 44th Annual Health Care Conference
Read more →BIIBBIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Biogen Inc. on behalf of its stockholders due to potential violations of federal securities laws. The investigation follows a subpoena from the Department of Justice regarding Biogen's international business operations. As a result of this news, Biogen's stock price experienced a significant decline, impacting investors. The law firm is encouraging shareholders who have faced losses to reach out for more information regarding their rights.
Read more →BIIBBiogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
Read more →BIIBBiogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
Read more →BIIBBiogen to Realign Resources for Alzheimer's Disease Franchise
Biogen has announced a strategic realignment of resources within its Alzheimer's disease franchise, focusing on advancing LEQEMBI and new treatments while discontinuing ADUHELM. This decision, which does not arise from safety or efficacy issues, includes a significant financial charge and the termination of the ENVISION study. By reallocating resources, Biogen aims to strengthen its position in the Alzheimer's market and explore additional innovative treatment options. The move reflects Biogen's commitment to meet patient needs amidst evolving challenges in Alzheimer's drug development.
Read more →BIIBBIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS FEBRUARY 13, 2024
BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS FEBRUARY 13, 2024
Read more →BIIB“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China
Read more →BIIBCentralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
Read more →BIIBCHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
Read more →BIIB“LEQEMBI® Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20
“LEQEMBI® Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20
Read more →BIIBBiogen to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Biogen to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Read more →BIIBBiogen Appoints Monish Patolawala to its Board of Directors
Biogen Inc. has appointed Monish Patolawala, the President and CFO of 3M Company, to its Board of Directors, effective January 1, 2024. Patolawala, who has over 25 years of financial leadership experience in global businesses, is expected to enhance the Board with his financial expertise. Biogen's leadership expressed optimism about his role in supporting the company's ongoing transformation and efforts to achieve sustainable growth. Patolawala has a notable background, having previously served as CFO of GE Healthcare and held various roles at General Electric.
Read more →BIIBEisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzhe
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzhe
Read more →BIIBBiogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
Biogen Inc. is set to present new data from its Alzheimer’s disease portfolio at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting from October 24-27 in Boston. The presentations will feature significant findings from the Phase 1b study evaluating tau reduction in early-stage Alzheimer’s patients, along with new data on LEQEMBI's subcutaneous administration. This event aims to provide deeper insights into treatment approaches and disease progression analytics that could impact patients and caregivers significantly.
Read more →BIIBBiogen Completes Acquisition of Reata Pharmaceuticals Reata acquisition bolsters Biogen s rare disease portfolio with the addition of SKYCLARYS (omaveloxolone), the first and only FDA approved treatment for Friedreich s
Biogen has completed the acquisition of Reata Pharmaceuticals, adding SKYCLARYS (omaveloxolone) to its portfolio, the first FDA-approved treatment for Friedreich's ataxia. This acquisition aligns with Biogen's strategy to serve patients with rare diseases and aims to create significant shareholder value. The launch of SKYCLARYS in the United States is underway, following over 1,000 patient start forms submitted. While the acquisition will slightly dilute Biogen's earnings in 2023, it is expected to become accretive by 2025.
Read more →BIIBLEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
Read more →BIIBBiogen Appoints Jane Grogan as Head of Research
Biogen Inc. has appointed Dr. Jane Grogan as Executive Vice President and Head of Research, effective October 2, 2023. With nearly two decades of biotechnology research experience, Dr. Grogan's previous roles include Chief Scientific Officer at Graphite Bio and ArsenalBio, as well as significant contributions at Genentech in immunology and oncology. Her expertise is expected to bolster Biogen's strategy in bringing innovative therapies to market. She will work alongside Dr. Priya Singhal to align the company's portfolio with its scientific capabilities.
Read more →BIIBBiogen to Acquire Reata Pharmaceuticals
Biogen to Acquire Reata Pharmaceuticals
Read more →BIIBCONFIDENTIAL
Biogen Inc. has agreed to acquire Reata Pharmaceuticals for $172.50 per share, resulting in an enterprise value of approximately $7.3 billion. This move is expected to enhance Biogen's portfolio with SKYCLARYS, the only approved treatment for Friedreich's ataxia in the United States. The acquisition is anticipated to positively impact Biogen's earnings starting in 2025, although it is expected to be dilutive in the short term. Biogen aims to leverage its expertise in rare diseases to effectively commercialize SKYCLARYS globally.
Read more →BIIBNew Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Read more →BIIBBiogen Announces 2023 Annual Shareholder Meeting Preliminary Results
Biogen Announces 2023 Annual Shareholder Meeting Preliminary Results
Read more →BIIBBiogen Announces Changes to Its Board of Directors
Biogen Announces Changes to Its Board of Directors
Read more →BIIBFDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Read more →BIIBBiogen Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental Biologics License Application for the Potential Traditional Approval of LEQEMBI in Early Alzheimer’s Disease
Biogen Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental Biologics License Application for the Potential Traditional Approval of LEQEMBI in Early Alzheimer’s Disease
Read more →BIIBStatement: Biogen Provides Update on Parkinson’s Disease Clinical Development Program
Statement: Biogen Provides Update on Parkinson’s Disease Clinical Development Program
Read more →BIIBHealth Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
Read more →BIIBBIOGEN PUBLISHES 2022 ESG REPORT
BIOGEN PUBLISHES 2022 ESG REPORT
Read more →BIIBDocument Strong progress toward three potential launches in 2023 Company reports first quarter 2023 results and reaffirms full year 2023 guidance First quarter 2023 financial results First quarter revenue $2,463 million
Biogen Inc. (BIIB) reported strong progress towards three potential launches in 2023, highlighting the FDA's Priority Review for LEQEMBI, a treatment for Alzheimer's disease. The first quarter financial results revealed a revenue of $2,463 million, although there was a 3% decline compared to the previous year. The company emphasized advancements in its R&D pipeline, including promising data for BIIB080 and a collaboration with Sage Therapeutics for zuranolone. However, Biogen also noted the deprioritization of some programs in its pipeline, alongside overall mixed revenue changes.
Read more →BIIBFDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
Read more →BIIBBiogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Read more →BIIBBiogen Appoints Adam Keeney as Head of Corporate Development
CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen’s Executive Committee r
Read more →BIIBNew Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
Read more →BIIBBiogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
Read more →BIIBBiogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA (dimethyl fumarate) Regulatory Data and Marketing Protection
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency (EMA), and the European Commission in their appeal of a General Court decision
Read more →BIIBBiogen Appoints Chuck Triano as Head of Investor Relations
Biogen Appoints Chuck Triano as Head of Investor Relations
Read more →BIIBA Statement from Biogen on Access to LEQEMBI™
A Statement from Biogen on Access to LEQEMBI™
Read more →BIIBFDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Read more →BIIBBiologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Read more →BIIBDocument Biogen advances significant potential growth drivers Company reports full year 2022 results and provides full year 2023 guidance Full year 2022 revenue and Non-GAAP EPS exceed guidance Fourth quarter revenue $2,
Biogen reported strong financial results for 2022, exceeding revenue and EPS guidance, driven by advancements in its Alzheimer's and depression treatment pipelines. The company received FDA approval for LEQEMBI, which could become a leading therapy for Alzheimer's disease, while zuranolone's application for major depressive disorder received Priority Review. However, Biogen anticipates a revenue decline in 2023, alongside challenges faced in their multiple sclerosis and biosimilar product lines, and has discontinued further development of its neuropathic pain treatment.
Read more →BIIBBiogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Read more →BIIBLecanemab Receives Priority Review Status in Japan
Lecanemab Receives Priority Review Status in Japan
Read more →BIIBMarketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
Read more →BIIBBiogen Shares Update on FDA Advisory Committee Meeting for Tofersen
Biogen Shares Update on FDA Advisory Committee Meeting for Tofersen
Read more →BIIBEISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN JAPAN
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN JAPAN
Read more →BIIBEisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Read more →BIIBBiogen Names Priya Singhal as Executive Vice President, Head of Development
CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that Priya Singhal, M.D., M.P.H., currently Head of Global Safety and Regulatory Sciences and Interim Head of Research & Development (R&D), has been promoted to Executive Vice President, Head
Read more →BIIBBiogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
Alcyone’s ThecaFlex DRx™ System is an implantable medical device in development for intrathecal drug delivery CAMBRIDGE, Mass. and LOWELL, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and colla
Read more →BIIBBiogen to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Biogen to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Read more →BIIBBiogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
Read more →BIIBFDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
Read more →BIIBBiogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Read more →BIIBSage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
Read more →BIIBEisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease (Ctad) Conference
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease (Ctad) Conference
Read more →BIIBBiogen Names Christopher Viehbacher President and Chief Executive Officer Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies
Biogen Names Christopher Viehbacher President and Chief Executive Officer Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies CAMBRIDGE, Mass., November 10, 2022: Biogen Inc. (NASDAQ: BIIB) today
Read more →BIIBBiogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
Data demonstrate potential of Manual Dexterity Test and Konectom™ smartphone-based technology in measuring MS disease progression Retrospective analysis applying machine learning, artificial intelligence and radiomics identifies brain imaging patterns that may further the unders
Read more →BIIBDocument Biogen Reports Third Quarter 2022 Results Third quarter revenue $2,508 million GAAP diluted EPS $7.84 Non-GAAP diluted EPS $4.77 Phase 3 study of lecanemab in early Alzheimer's disease met the primary endpoint a
Biogen Reports Third Quarter 2022 Results Third quarter revenue $2,508 million GAAP diluted EPS $7.84 Non-GAAP diluted EPS $4.77 Phase 3 study of lecanemab in early Alzheimer's disease met the primary endpoint and all key secondary endpoints with highly statistically significan
Read more →BIIBBiogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is April 25, 2023 CAMBRIDGE, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the new d
Read more →BIIBBiogen and Sage Therapeutics Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
Biogen and Sage Therapeutics Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
Read more →BIIBBiogen Announces First Patient Dosed in Pivotal Study of Litifilimab in Cutaneous Lupus Erythematosus, an Autoimmune Disease Affecting Skin
Biogen Announces First Patient Dosed in Pivotal Study of Litifilimab in Cutaneous Lupus Erythematosus, an Autoimmune Disease Affecting Skin
Read more →BIIBBiogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
Read more →BIIBBiogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA (tocilizumab)
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA®1 (tocilizumab), an anti-interle
Read more →BIIBLECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
Read more →BIIBStatement: Biogen Statement On Qui Tam Settlement
Statement: Biogen Statement On Qui Tam Settlement
Read more →BIIBThe New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS
The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS
Read more →BIIBThe New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus
Read more →BIIBStatement on Alzheimer’s & Dementia® Journal Publication about Association between Reduction of Amyloid Beta and Slowing of Cognitive and Functional Decline in Alzheimer’s Disease
Statement on Alzheimer’s & Dementia® Journal Publication about Association between Reduction of Amyloid Beta and Slowing of Cognitive and Functional Decline in Alzheimer’s Disease
Read more →BIIBBiogen to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Biogen to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Read more →BIIBEISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022
EISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022
Read more →BIIBThe New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
Read more →BIIBFDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
Read more →BIIB▼ -5.8%on this news
Document Biogen Reports Second Quarter 2022 Results Second quarter revenue $2,589 million GAAP diluted EPS $7.24 Non-GAAP diluted EPS $5.25 FDA granted Priority Review for lecanemab in early Alzheimer's disease under the
Biogen Reports Second Quarter 2022 Results Second quarter revenue $2,589 million GAAP diluted EPS $7.24 Non-GAAP diluted EPS $5.25 FDA granted Priority Review for lecanemab in early Alzheimer's disease under the accelerated approval pathway with a decision expected by January 6
Read more →BIIB▼ -5.8%on this news
Biogen Reports Second Quarter 2022 Results
Biogen Reports Second Quarter 2022 Results
Read more →BIIBThe U.S. FDA Accepts and Grants Priority Review for EISAI’s Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
The U.S. FDA Accepts and Grants Priority Review for EISAI’s Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
Read more →BIIBBiogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
Read more →BIIBEuropean Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)
European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)
Read more →BIIBNew Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)
New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)
Read more →BIIBBiogen Appreciation Statement for Retiring Board Members Nancy Leaming and Brian Posner
Biogen Appreciation Statement for Retiring Board Members Nancy Leaming and Brian Posner
Read more →BIIBBiogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
Cambridge, Mass. and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) -- Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease AL01811 is a preclinical selecti
Read more →BIIBBiogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
CAMBRIDGE, Mass. and GUANGZHOU, China, June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 data for BIIB800 (BAT1806), a biosimilar candidate referencing ACTEMRA®/ROACTEMRA® (tocilizumab), anti-in
Read more →BIIBBiogen and Samsung Bioepis’ BYOOVIZ™ (ranibizumab-nuna) Launches in the United States
Biogen and Samsung Bioepis’ BYOOVIZ™ (ranibizumab-nuna) Launches in the United States
Read more →BIIBDenali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
Read more →BIIBEISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Read more →BIIBBiogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
Read more →BIIBDocument BIOGEN REPORTS FIRST QUARTER 2022 RESULTS First quarter revenue $2,532 million GAAP diluted EPS $2.06 Non-GAAP diluted EPS $3.62 EPS negatively impacted by $0.76 due to ADUHELM inventory write-offs As a result o
BIOGEN REPORTS FIRST QUARTER 2022 RESULTS First quarter revenue $2,532 million GAAP diluted EPS $2.06 Non-GAAP diluted EPS $3.62 EPS negatively impacted by $0.76 due to ADUHELM inventory write-offs As a result of the final national coverage determination for antibodies directe
Read more →BIIBBiogen to Report First Quarter 2022 Financial Results May 3, 2022
Biogen to Report First Quarter 2022 Financial Results May 3, 2022
Read more →BIIBBiogen Statement Regarding Updated ADUHELM® (aducanumab-avwa) Prescribing Information in US
Biogen Statement Regarding Updated ADUHELM® (aducanumab-avwa) Prescribing Information in US
Read more →BIIBUpdate on Regulatory Submission for Aducanumab in the European Union
Update on Regulatory Submission for Aducanumab in the European Union
Read more →BIIBBiogen Completes Sale of Equity Stake in Biosimilar Joint Venture to Samsung Biologics for $2.3 Billion
Biogen Completes Sale of Equity Stake in Biosimilar Joint Venture to Samsung Biologics for $2.3 Billion
Read more →BIIBBiogen’s Statement on the Final National Coverage Determination for Amyloid-Beta Targeting Therapies for the Treatment of Alzheimer’s Disease
Biogen’s Statement on the Final National Coverage Determination for Amyloid-Beta Targeting Therapies for the Treatment of Alzheimer’s Disease
Read more →BIIBNew Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression
New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression
Read more →BIIBBiogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
Read more →BIIBBiogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Read more →BIIBLatest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting
Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting
Read more →BIIBThe National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence White Paper
The National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence White Paper
Read more →BIIBLong-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
Read more →BIIBBiogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
Read more →BIIBBiogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
Read more →BIIBBiogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
Read more →BIIBBiogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
Read more →BIIBEISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB
EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB
Read more →BIIBBIOGEN DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $200,000 In Biogen To Contact Him Directly To Discuss Their Options
NEW YORK, Feb. 19, 2022 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biogen, Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) and reminds investors of the April 8, 2022 deadline to seek the role of lead
Read more →BIIBBiogen to Present at the Cowen 42nd Annual Health Care Conference
Biogen to Present at the Cowen 42nd Annual Health Care Conference
Read more →BIIBBIOGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Biogen, Inc. in the United States District Court for the District of Massachusetts
NEW YORK, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or oth
Read more →BIIBSage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
Read more →BIIBBiogen Submits Response to the Centers for Medicare and Medicaid Services (CMS) Proposed National Coverage Determination (NCD) for Anti-Amyloid Treatments in Alzheimer’s Disease
Biogen Submits Response to the Centers for Medicare and Medicaid Services (CMS) Proposed National Coverage Determination (NCD) for Anti-Amyloid Treatments in Alzheimer’s Disease
Read more →BIIBBiogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
CAMBRIDGE, Mass and SOLNA, Sweden, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Xbrane Biopharma AB (STO: XBRANE) today announced that they have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane™, a prec
Read more →BIIBDocument BIOGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS Revenue Fourth quarter $2,734 million Full Year $10,982 million GAAP diluted EPS Fourth quarter $2.50 Full Year $10.40 Non-GAAP diluted EPS Fourth quarter
BIOGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS Revenue Fourth quarter $2,734 million Full Year $10,982 million GAAP diluted EPS Fourth quarter $2.50 Full Year $10.40 Non-GAAP diluted EPS Fourth quarter $3.39 Full Year $19.22 Engaging with Centers for Medicare and Me
Read more →BIIBBiogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
Read more →BIIBBiogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors CAMBRIDGE, Mass., January 31, 2022 Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner will retire from Biogen s Board of Directors, effective at the time of the Company
Read more →BIIBBiogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
Read more →BIIBUpdate on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
Read more →BIIBBiogen’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
Biogen’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
Read more →BIIBBiogen to Host Analyst Q&A Call
Biogen to Host Analyst Q&A Call
Read more →BIIBBiogen to Present at the 40th Annual J.P. Morgan Healthcare Conference
Biogen to Present at the 40th Annual J.P. Morgan Healthcare Conference
Read more →BIIBBiogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Read more →BIIBJapan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review
Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review
Read more →BIIBBiogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease
Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease
Read more →BIIBUpdate on the Phase 4 Confirmatory Study of ADUHELM®
Update on the Phase 4 Confirmatory Study of ADUHELM®
Read more →BIIBBiogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
Read more →BIIBSage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
Read more →BIIBUpdate on Regulatory Review of Aducanumab in the European Union
Update on Regulatory Review of Aducanumab in the European Union
Read more →BIIBBiogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development
Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development CAMBRIDGE, Mass., November 15, 2021 Biogen Inc. (Nasdaq: BIIB) announced today that Alfred Al W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company effectiv
Read more →BIIBBiogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
Biogen earns top ESG leadership scores on areas including Innovation Management and Climate Strategy, highlighting efforts to address urgent and long-term challenges facing humanity In 2021, Biogen notably bolstered its longstanding corporate responsibility leadership actions by
Read more →BIIBNew Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
Read more →BIIBEisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2B Study at Clinical Trials on Alzheimer's Disease (CTAD) Conference
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2B Study at Clinical Trials on Alzheimer's Disease (CTAD) Conference
Read more →BIIBEisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2B Study Core and Open-Label Extension Across Five Years at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2B Study Core and Open-Label Extension Across Five Years at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Read more →BIIBBiogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Read more →BIIBA Letter from Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It’s Time for Companies to Act Like the Climate Crisis is a Health Crisis
A Letter from Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It’s Time for Companies to Act Like the Climate Crisis is a Health Crisis
Read more →BIIBBiogen Reports Third Quarter 2021 Results
Biogen Reports Third Quarter 2021 Results
Read more →BIIBBiogen to Report Third Quarter 2021 Financial Results October 20, 2021
Biogen to Report Third Quarter 2021 Financial Results October 20, 2021
Read more →BIIBDocument BIOGEN REPORTS THIRD QUARTER 2021 RESULTS Third quarter revenue $2,779 million GAAP diluted EPS $2.22 Non-GAAP diluted EPS $4.77 Rolling submission initiated for lecanemab (BAN2401) in the U.S. and new data pres
BIOGEN REPORTS THIRD QUARTER 2021 RESULTS Third quarter revenue $2,779 million GAAP diluted EPS $2.22 Non-GAAP diluted EPS $4.77 Rolling submission initiated for lecanemab (BAN2401) in the U.S. and new data presented for aducanumab and BIIB080 (tau ASO) Phase 3 data reported
Read more →BIIBSage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
Read more →BIIBBiogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
Read more →BIIBTopline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
Read more →BIIBNew Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience
New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience
Read more →BIIBNew MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
Read more →BIIBSage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress
Read more →BIIBEisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
Read more →BIIBBiogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative
Read more →BIIBBiogen Announces Investor Day on September 21, 2021
Biogen Announces Investor Day on September 21, 2021
Read more →BIIBBiogen Announces Agenda for Virtual Investor Day R&D Day on September 21, 2021
Biogen Announces Agenda for Virtual Investor Day R&D Day on September 21, 2021
Read more →BIIBBiogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
Read more →BIIBBiogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
33 early and late-stage clinical programs across modalities and innovative discovery platforms Uniquely positioned to lead in Alzheimer’s disease with ADUHELM® (aducanumab-avwa) and industry-leading pipeline including Phase 3 lecanemab Potential to transform standard of care in
Read more →BIIBBiogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Read more →BIIBBiogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
Read more →BIIBBiogen to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
Biogen to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
Read more →BIIBBiogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
Read more →BIIBLate-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)
Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)
Read more →BIIBBiogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
Read more →BIIBBiogen and Ionis report positive topline clinical data on investigational Alzheimer’s disease treatment at AAIC
Biogen and Ionis report positive topline clinical data on investigational Alzheimer’s disease treatment at AAIC
Read more →BIIBBiogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
Read more →BIIBBiogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference
Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference
Read more →BIIBAn open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.
An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.
Read more →BIIBBiogen to Report Second Quarter 2021 Financial Results July 22, 2021
Biogen to Report Second Quarter 2021 Financial Results July 22, 2021
Read more →BIIBBiogen Reports Second Quarter 2021 Results
Biogen Reports Second Quarter 2021 Results
Read more →BIIBDocument BIOGEN REPORTS SECOND QUARTER 2021 RESULTS Second quarter revenue $2,775 million GAAP diluted EPS $2.99 Non-GAAP diluted EPS $5.68 Received accelerated approval for ADUHELM (aducanumab-avwa) in the U.S. for init
BIOGEN REPORTS SECOND QUARTER 2021 RESULTS Second quarter revenue $2,775 million GAAP diluted EPS $2.99 Non-GAAP diluted EPS $5.68 Received accelerated approval for ADUHELM (aducanumab-avwa) in the U.S. for initiation of treatment in patients with mild cognitive impairment or
Read more →BIIBBiogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
Read more →BIIBFDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
Read more →BIIBCollaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
Read more →BIIBEISAI and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation for LECANEMAB (BAN2401), an Anti-Amyloid Beta Protofibril Antibody for the Treatment of Alzheimer's Disease
EISAI and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation for LECANEMAB (BAN2401), an Anti-Amyloid Beta Protofibril Antibody for the Treatment of Alzheimer's Disease
Read more →BIIBBiogen and Eisai Update for the Alzheimer’s Disease Community
Biogen and Eisai Update for the Alzheimer’s Disease Community
Read more →BIIBBiogen to Participate in SVB Leerink’s 3rd Annual CNS Forum
Biogen to Participate in SVB Leerink’s 3rd Annual CNS Forum
Read more →BIIBBiogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
Read more →BIIBBiogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
Read more →BIIBSage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Read more →BIIBBiogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
The Phase 3 STAR study did not meet primary or key secondary endpoints Choroideremia is a rare inherited retinal disease that results in progressive vision loss, ultimately leading to blindness CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today
Read more →BIIBNew Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy
New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy
Read more →BIIBA Letter from Biogen’s CEO on ADUHELM
A Letter from Biogen’s CEO on ADUHELM
Read more →BIIBFDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
Read more →BIIBBiogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™
Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™
Read more →BIIBBiogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra (Tocilizumab)
CAMBRIDGE, Mass. and GUANGZHOU, China, June 01, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced results from the Phase 3 study of BAT1806, a proposed biosimilar referencing ACTEMRA®/RoACTEMRA® (tocilizumab). The study
Read more →BIIBBiogen Announces Webcast of Annual Meeting of Stockholders
Biogen Announces Webcast of Annual Meeting of Stockholders
Read more →BIIBBiogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
Collaboration aims to develop a next-generation AAV production platform to help accelerate Biogen’s efforts to bring novel gene therapies to patients worldwide Ginkgo’s synthetic biology expertise may enable the expansion of therapeutic utility and overcome development challenge
Read more →BIIBSwissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland
Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland
Read more →BIIBBiogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
Read more →BIIBBiogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
Read more →BIIBBiogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data
TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile Acute ischemic stroke is caused by a blockage of blood supply to the brain, and current thrombolytics are limited in use due in part to increased risks of bleeding Phase 2a stud
Read more →BIIBBiogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
Read more →BIIBBiogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics
Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics
Read more →BIIBBiogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)
Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)
Read more →BIIBBiogen to Report First Quarter 2021 Financial Results April 22, 2021
Biogen to Report First Quarter 2021 Financial Results April 22, 2021
Read more →BIIBBiogen Reports First Quarter 2021 Results
Biogen Reports First Quarter 2021 Results
Read more →BIIBDocument BIOGEN REPORTS FIRST QUARTER 2021 RESULTS First quarter revenue $2,694 million GAAP diluted EPS $2.69 Non-GAAP diluted EPS $5.34 2021 earnings guidance raised Regulatory filings for aducanumab submitted in addit
BIOGEN REPORTS FIRST QUARTER 2021 RESULTS First quarter revenue $2,694 million GAAP diluted EPS $2.69 Non-GAAP diluted EPS $5.34 2021 earnings guidance raised Regulatory filings for aducanumab submitted in additional global markets Phase 2 study of BIIB124 (SAGE-324) in essen
Read more →BIIBBiogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
Read more →BIIB18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy
Read more →BIIBNew Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
Read more →BIIBBiogen Grows Presence in China with the Approval of TECFIDERA (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needs More than 500,000 individuals worldwide living with multiple sclerosis (MS) have been treated with TECFIDERA, which has a well-establ
Read more →BIIBBiogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021
Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021
Read more →BIIBSage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Read more →BIIBDocument Biogen Announces Two New Nominees for Election to Board of Directors Nominees bring diverse business and public health experience key to Biogen's mission to pioneer and lead in neuroscience Company thanks Direct
Biogen Announces Two New Nominees for Election to Board of Directors Nominees bring diverse business and public health experience key to Biogen's mission to pioneer and lead in neuroscience Company thanks Director Robert W. Pangia as he retires from the Board CAMBRIDGE, Mass.,
Read more →BIIBBiogen Announces Two New Nominees for Election to Board of Directors
Biogen Announces Two New Nominees for Election to Board of Directors
Read more →BIIBBiogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA® (tocilizumab) Biosimilars have the potential to enable greater access to marketed biologic therapies while generating cost s
Read more →BIIBBiogen to Participate in the Stifel 3rd Annual CNS Day
Biogen to Participate in the Stifel 3rd Annual CNS Day
Read more →BIIBBiogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
Read more →BIIBBiogen to Webcast Aducanumab Presentations from AD/PD 2021 Virtual Conference on March 9-13, 2021
Biogen to Webcast Aducanumab Presentations from AD/PD 2021 Virtual Conference on March 9-13, 2021
Read more →BIIBLife Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program
Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program
Read more →BIIBBiogen to Participate in Webinar with the Global Alzheimer's Platform Foundation on February 23, 2021
Biogen to Participate in Webinar with the Global Alzheimer's Platform Foundation on February 23, 2021
Read more →BIIBBiogen to Participate in the Cowen 41st Annual Health Care Conference
Biogen to Participate in the Cowen 41st Annual Health Care Conference
Read more →BIIBBiogen Announces the Expiration Date Results of Its Cash Tender Offer
Biogen Announces the Expiration Date Results of Its Cash Tender Offer
Read more →BIIBBiogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups
Golden Tickets winners Bolden Therapeutics and Seranova Bio will have access to a state-of-the-art lab facilities at LabCentral with mentorship and support from Biogen CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and LabCentral today announced B
Read more →BIIBBiogen Announces the Pricing Terms of Its Private Exchange Offer
Biogen Announces the Pricing Terms of Its Private Exchange Offer
Read more →BIIBBiogen Announces the Pricing Terms of its Cash Tender Offer
CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the pricing terms of its previously announced offer to purchase for cash (the “Cash Offer”) its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion
Read more →BIIBBiogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the commencement of an offer to purchase for cash (the “Cash Offer”) any and all of its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion in aggr
Read more →BIIBBIOGEN ANNOUNCES PRIVATE EXCHANGE OFFER FOR 5.200% SENIOR NOTES DUE 2045 OPEN TO CERTAIN INVESTORS Cambridge, Mass.
BIOGEN ANNOUNCES PRIVATE EXCHANGE OFFER FOR 5.200% SENIOR NOTES DUE 2045 OPEN TO CERTAIN INVESTORS Cambridge, Mass., February 4, 2021 Biogen Inc. ( Biogen ) (Nasdaq: BIIB) today announced the commencement of a private offer to exchange (the Exchange Offer ) any and all of its
Read more →BIIBBiogen to Report Fourth Quarter and Full Year 2020 Financial Results February 3, 2021
Biogen to Report Fourth Quarter and Full Year 2020 Financial Results February 3, 2021
Read more →BIIBDocument BIOGEN REPORTS FOURTH QUARTER AND FULL YEAR 2020 RESULTS Revenue Fourth quarter $2,853 million Full Year $13,445 million GAAP diluted EPS Fourth quarter $2.32 Full Year $24.80 Non-GAAP diluted EPS Fourth quarter
BIOGEN REPORTS FOURTH QUARTER AND FULL YEAR 2020 RESULTS Revenue Fourth quarter $2,853 million Full Year $13,445 million GAAP diluted EPS Fourth quarter $2.32 Full Year $24.80 Non-GAAP diluted EPS Fourth quarter $4.58 Full Year $33.70 Aducanumab for Alzheimer's disease curren
Read more →BIIBBiogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
Read more →BIIBBiogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
Read more →BIIBBiogen to Participate in Webinar with Alzheimer's Disease International on January 14, 2021
Biogen to Participate in Webinar with Alzheimer's Disease International on January 14, 2021
Read more →BIIBA statement about Biogen Political Action Committee
A statement about Biogen Political Action Committee
Read more →BIIBBiogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
Read more →BIIBBiogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
Read more →BIIBThe European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
Read more →BIIBBiogen Files New Drug Application for Aducanumab in Japan
Biogen Files New Drug Application for Aducanumab in Japan
Read more →BIIBBiogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Read more →BIIBSamsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)
Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)
Read more →BIIBBiogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership
Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership
Read more →BIIBBIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of investors tha
Read more →BIIBBIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen, Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Biogen, Inc. (NASDAQ: BIIB) on behalf of Biogen stockholders. Our investigation concerns whether Biogen has viol
Read more →BIIBUpdate on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease
Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease
Read more →BIIBBiogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020
Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020
Read more →BIIBBiogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting
In Phase 2 LILAC study, BIIB059 demonstrated a statistically significant reduction in joint disease activity compared to placebo in systemic lupus erythematosus patients Positive results build on previously reported cutaneous lupus erythematosus data and underscore Biogen’s comm
Read more →BIIBEuropean Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease
European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease
Read more →BIIBBiogen Reports Q3 2020 Results
Biogen Reports Q3 2020 Results
Read more →BIIBBiogen to Report Third Quarter 2020 Financial Results October 21, 2020
Biogen to Report Third Quarter 2020 Financial Results October 21, 2020
Read more →BIIBDocument BIOGEN REPORTS Q3 2020 RESULTS Third quarter revenue $3,376 million GAAP diluted EPS $4.46 Non-GAAP diluted EPS $8.84 FDA accepted Biologics License Application for aducanumab with Priority Review Marketing Auth
BIOGEN REPORTS Q3 2020 RESULTS Third quarter revenue $3,376 million GAAP diluted EPS $4.46 Non-GAAP diluted EPS $8.84 FDA accepted Biologics License Application for aducanumab with Priority Review Marketing Authorization Application for aducanumab submitted in Europe New col
Read more →BIIBSamsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)
Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)
Read more →BIIBStatement about the FDA advisory committee on aducanumab
Statement about the FDA advisory committee on aducanumab
Read more →BIIBStatement to ICER’s announced plans to conduct an assessment on the value of aducanumab
Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab
Read more →BIIBBiogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health
Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health
Read more →BIIBNew Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS
New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS
Read more →BIIBBiogen to Webcast Prerecorded Encore Aducanumab Presentation from 61st Annual Meeting of the Japanese Society of Neurology on August 31, 2020
Biogen to Webcast Prerecorded Encore Aducanumab Presentation from 61st Annual Meeting of the Japanese Society of Neurology on August 31, 2020
Read more →BIIBFDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
Read more →BIIBBiogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
Read more →BIIBBiogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease
Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease
Read more →BIIBOther Financial Highlights
BIOGEN REPORTS Q2 2020 REVENUES OF $3.7 BILLION GAAP diluted EPS increased 22%; Non-GAAP diluted EPS increased 12% Biogen completed submission of BLA for aducanumab in Alzheimer's disease in the U.S. New SPINRAZA data showed unprecedented survival in pre-symptomatic SMA Bioge
Read more →BIIBBiogen to Report Second Quarter 2020 Financial Results July 22, 2020
Biogen to Report Second Quarter 2020 Financial Results July 22, 2020
Read more →BIIBBiogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer
Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer CAMBRIDGE, Mass. July 21, 2020 Biogen Inc. (Nasdaq: BIIB) announced today the appointment of Michael (Mike) McDonnell as Executive Vice President and Chief Financial Officer, effective August
Read more →BIIBBiogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA (nusinersen) in Patients Treated with Zolgensma (onasemnogene abeparvovec)
In the long-term follow-up study of Zolgensma® and real-world experience, it has been reported that some patients previously treated with gene therapy have been treated with SPINRAZA1,2,3 The RESPOND study aims to evaluate the efficacy and safety of SPINRAZA in patients with a s
Read more →BIIBInitiation of New Phase III Clinical Study (AHEAD 3-45) of BAN2401 Preclinical (Asymptomatic) Alzheimer’s Disease
Initiation of New Phase III Clinical Study (AHEAD 3-45) of BAN2401 Preclinical (Asymptomatic) Alzheimer’s Disease
Read more →BIIBThe New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
Read more →BIIBBiogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease
Read more →BIIBNew Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment
New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment
Read more →BIIBBiogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
Read more →BIIBBiogen Statement about Director Lynn Schenk
Biogen Statement about Director Lynn Schenk
Read more →BIIBBiogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science
Read more →BIIBNew Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS
New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS
Read more →BIIBBiogen to Webcast Prerecorded Encore Aducanumab Presentation from AAN Science Highlights Virtual Platform on May 18, 2020
Biogen to Webcast Prerecorded Encore Aducanumab Presentation from AAN Science Highlights Virtual Platform on May 18, 2020
Read more →BIIBNew SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients
New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients
Read more →BIIBBiogen to Participate at World Medical Innovation Forum Virtual Gathering: COVID-19 on May 11, 2020
Biogen to Participate at World Medical Innovation Forum Virtual Gathering: COVID-19 on May 11, 2020
Read more →BIIBBiogen Prices $3.0 Billion of Senior Unsecured Notes
CAMBRIDGE, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the pricing of two series of senior unsecured notes for an aggregate principal amount of $3.0 billion. The notes will mature as follows: $1.5 billion will mature on May 1, 2030 and wi
Read more →BIIBBiogen to Report First Quarter 2020 Financial Results April 22, 2020
Biogen to Report First Quarter 2020 Financial Results April 22, 2020
Read more →BIIBBiogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics
Continued to improve absolute environmental performance across energy, water and waste metrics while growing the business in 2019; has remained carbon neutral for six years in a row Advanced health equity and diversity goals; 46% of Biogen’s director-level positions and above ar
Read more →BIIBBiogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank
Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank
Read more →BIIBBiogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study
Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study
Read more →BIIBBiogen to Webcast Encore Aducanumab Presentation From Virtual AAT-AD/PD Meeting on April 2, 2020
Biogen to Webcast Encore Aducanumab Presentation From Virtual AAT-AD/PD Meeting on April 2, 2020
Read more →BIIBBiogen Statement: Business Update Regarding COVID-19
Biogen Statement: Business Update Regarding COVID-19
Read more →BIIBBiogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World
Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World
Read more →BIIBBiogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Read more →BIIBBiogen to Present at the Cowen 40th Annual Health Care Conference
Biogen to Present at the Cowen 40th Annual Health Care Conference
Read more →BIIBBiogen Reports Full Year 2019 Revenues of $14.4 Billion
Biogen Reports Full Year 2019 Revenues of $14.4 Billion
Read more →BIIBBiogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.
Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.
Read more →BIIBBiogen to Present at the 38th Annual J.P. Morgan Healthcare Conference
Biogen to Present at the 38th Annual J.P. Morgan Healthcare Conference
Read more →BIIBBiogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy
Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy
Read more →BIIBBiogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
Read more →BIIBBiogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
The Phase 2 LILAC study met its primary endpoints, demonstrating statistically significant reduction of disease activity in patients with CLE and SLE who received BIIB059 compared to placebo Positive results support Biogen’s goal of building a multi-franchise portfolio and under
Read more →BIIBBiogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)
Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)
Read more →BIIBBiogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the enrollment of the last patient in the global Phase 3 STAR clinical study, which is evaluating the investigational gene therapy timrepigene emparvovec (BIIB111/AAV2-REP1) for the tre
Read more →BIIBBiogen to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Biogen to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Read more →BIIBBiogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis
Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis
Read more →BIIBBiogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemi
Read more →BIIBBiogen Reports Q3 2019 Revenues of $3.6 Billion
Biogen Reports Q3 2019 Revenues of $3.6 Billion
Read more →BIIBBiogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Read more →BIIBBiogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week
Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week
Read more →BIIBLandmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders
Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders
Read more →BIIBBiogen Announces Leadership Update
Biogen Announces Leadership Update
Read more →BIIBInterferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding
Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding
Read more →BIIBBiogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
Read more →BIIBBiogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index
CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI World) for the fourth time, after being the first U.S.-based biotech company to e
Read more →BIIBNew Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum
New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum
Read more →BIIBBiogen to Report Third Quarter 2019 Financials October 22,2019
Biogen to Report Third Quarter 2019 Financials October 22,2019
Read more →BIIBNew Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years
New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years
Read more →BIIBBiogen to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
Biogen to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
Read more →BIIBBiogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
New SMA STAT genetic test reduces time to provide results from 21 to four days to aid in clinical care Early treatment of SMA has been shown to slow disease progression and improve or stabilize loss of motor function SMA Identified program offers genetic testing for SMA at no c
Read more →BIIBDiroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Read more →BIIBBiogen Q2 2019 Revenues Increased 8% to $3.6 Billion
Biogen Q2 2019 Revenues Increased 8% to $3.6 Billion
Read more →BIIBBiogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Read more →BIIBBiogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy
Label update includes data from four clinical studies including long-term safety and efficacy data across a broad Spinal Muscular Atrophy (SMA) population Data from over 300 patients across a broad range of ages and types of Spinal Muscular Atrophy (SMA) who have received treatm
Read more →BIIBBiogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019
Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019
Read more →BIIBBiogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
Read more →BIIBBiogen to Host Investor Webcast to Discuss ALS Portfolio on June 5, 2019
Biogen to Host Investor Webcast to Discuss ALS Portfolio on June 5, 2019
Read more →BIIBNew Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
Read more →BIIBBiogen to Present at Bernstein’s 35th Annual Strategic Decisions Conference
Biogen to Present at Bernstein’s 35th Annual Strategic Decisions Conference
Read more →BIIBBiogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation
Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation
Read more →BIIBBiogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
Read more →BIIBData at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS
Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS
Read more →BIIBBiogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)
Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)
Read more →BIIBBiogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
Read more →BIIBBiogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
Read more →BIIBData Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy
Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy
Read more →BIIBBiogen Announces Three New Nominees for Election to Board of Directors
Biogen Announces Three New Nominees for Election to Board of Directors
Read more →BIIBBiogen to Report First Quarter 2019 Financial Results April 24, 2019
Biogen to Report First Quarter 2019 Financial Results April 24, 2019
Read more →BIIBBiogen Q1 2019 Revenues Increased 11% to $3.5 Billion
Biogen Q1 2019 Revenues Increased 11% to $3.5 Billion
Read more →BIIBBiogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference
Adults with later-onset spinal muscular atrophy (SMA) who are not being treated show increased rates of hospital admissions, clinical interventions and mortality, indicating an unmet medical need Infants with pre-symptomatic SMA treated with SPINRAZA® (nusinersen) achieve motor
Read more →BIIBBiogen to Present at the Stifel First Annual CNS Day
Biogen to Present at the Stifel First Annual CNS Day
Read more →BIIBBiogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mil
Read more →BIIBBiogen to Present at the Cowen 39th Annual Health Care Conference
Biogen to Present at the Cowen 39th Annual Health Care Conference
Read more →BIIBBiogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology
Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology
Read more →BIIBBiogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA
·Canadian Association of Drugs and Technologies in Health (CADTH) has expanded their recommendations for public reimbursement for SMA patients ·The recommendation, however, continues to limit access to treatment for many patients with SMA ·Provincial jurisdictions are the final
Read more →BIIBBiogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy
Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy
Read more →BIIBAlkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
Read more →BIIBBiogen to Report Fourth Quarter and Year-End 2018 Financial Results January 29, 2019
Biogen to Report Fourth Quarter and Year-End 2018 Financial Results January 29, 2019
Read more →BIIBBiogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
Read more →BIIBBiogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions
C4T’s targeted protein degradation platform provides a novel approach to neuroscience drug discovery and development, complementing Biogen’s broader research and development efforts across multiple modalities CAMBRIDGE, Mass. and WATERTOWN, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE)
Read more →BIIBBiogen Applauds Quebec Decision to Cover SPINRAZA™ (nusinersen) for a broad population of SMA Patients
The decision follows positive recommendation from the Institut national d'excellence en santé et services sociaux (INESSS) recognising the urgency and need for a treatment for patients with SMA and the robust clinical data of nusinersen SPINRAZA will be listed on the hospital fo
Read more →BIIBBiogen to Present at the 37th Annual J.P. Morgan Healthcare Conference
Biogen to Present at the 37th Annual J.P. Morgan Healthcare Conference
Read more →BIIBAlkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
Read more →BIIBBiogen To Host Investor Webcast On Its Multiple Sclerosis Portfolio On December 12, 2018
Biogen To Host Investor Webcast On Its Multiple Sclerosis Portfolio On December 12, 2018
Read more →BIIBBiogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067 Biogen plans to advance BIIB067 to a pivotal clinical study Biogen paid Ionis Pharmaceuticals a $35 million one-time upfront payment and may pay potential milestone payments and royalties
Read more →BIIBInternational Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
Read more →BIIBBiogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)
Read more →BIIBBiogen to Report Third Quarter 2018 Financial Results October 23, 2018
Biogen to Report Third Quarter 2018 Financial Results October 23, 2018
Read more →BIIBUCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Read more →BIIBBiogen Q3 2018 Revenues Increased 12% to $3.4 Billion
Biogen Q3 2018 Revenues Increased 12% to $3.4 Billion
Read more →BIIBBiogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Read more →BIIBIMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union
IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union
Read more →BIIBBiogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
Read more →BIIBNew SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
Read more →BIIBBiogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease Meeting on October 25-26, 2018
Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease Meeting on October 25-26, 2018
Read more →BIIBBiogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
Read more →BIIBBiogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
Read more →BIIBBiogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction
Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction
Read more →BIIBBiogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced results from a recent analysis of the ongoing long-term extension (LTE) Phase 1b study of aducanumab, an investigational treatm
Read more →BIIBEisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
Read more →BIIBBiogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018
Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018
Read more →BIIBEisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
Read more →BIIBBiogen to Report Second Quarter 2018 Financial Results on July 24, 2018
Biogen to Report Second Quarter 2018 Financial Results on July 24, 2018
Read more →BIIBBiogen Q2 2018 Revenues Increase 9% to $3.4 Billion
Biogen Q2 2018 Revenues Increase 9% to $3.4 Billion
Read more →BIIBData to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)
Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)
Read more →BIIBBiogen Exercises Option to Increase Ownership in Samsung Bioepis
Biogen Exercises Option to Increase Ownership in Samsung Bioepis
Read more →BIIBBiogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018
CAMBRIDGE, Mass., June 19, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing an overview of its efforts targeting acute ischemic stroke on Thursday, June 28, 2018. The live webcast will be from 8:00-9:00 a.m. ET with Michael Ehle
Read more →BIIBBiogen Foundation Selects Grantees to Receive $10 Million Investment for STEM Education
CAMBRIDGE, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- The Biogen Foundation today announced the six nonprofits that will share a previously-announced four-year, $10 million grant to drive the development of local STEM (science, technology, engineering, and math) education ecosystem
Read more →BIIBSamsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF Biosimilars BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) at EULAR 2018
Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF Biosimilars BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) at EULAR 2018
Read more →BIIBBiogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
Read more →BIIBBiogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke
Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke
Read more →BIIBPhase II Clinical Study of Elenbecestat Demonstrates Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months
Phase II Clinical Study of Elenbecestat Demonstrates Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months
Read more →BIIBBiogen Appoints Daniel Karp as EVP, Corporate Development
Biogen Appoints Daniel Karp as EVP, Corporate Development
Read more →BIIBBiogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab
Read more →BIIBBiogen to Report First Quarter 2018 Financial Results on April 24, 2018
Biogen to Report First Quarter 2018 Financial Results on April 24, 2018
Read more →BIIBBiogen Reports Quarterly Revenues of $3.1 Billion
Biogen Reports Quarterly Revenues of $3.1 Billion
Read more →BIIBBiogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases
Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases
Read more →BIIBBiogen to Present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting
Biogen to Present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting
Read more →BIIBBiogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting
Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting
Read more →BIIBBiogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia
Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia
Read more →BIIBNew Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen)
New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen)
Read more →BIIBBiogen to Present at the Cowen and Company 38th Annual Health Care Conference
Biogen to Present at the Cowen and Company 38th Annual Health Care Conference
Read more →BIIBThe New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
Read more →BIIBBiogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke
Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke
Read more →BIIBBiogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing
Read more →BIIBBiogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively
Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively
Read more →BIIBBiogen Foundation Commits $10 Million to STEM Education in Cambridge and Somerville
Biogen Foundation Commits $10 Million to STEM Education in Cambridge and Somerville
Read more →BIIBAdaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint
Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint
Read more →BIIBBiogen to Present at the 36th Annual J.P. Morgan Healthcare Conference
Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference
Read more →BIIBBiogen Appoints Mark Hernon as SVP, Chief Information Officer
Biogen Appoints Mark Hernon as SVP, Chief Information Officer
Read more →BIIBBiogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer
Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer
Read more →BIIBBiogen Matt Fearer Ph: +1 781 464 3260 public.affairs@biogen.com INVESTOR CONTACT: Biogen Matt Calistri Ph: +1 781 464 2442 IR@biogen.com
BIOGEN APPOINTS JEFF CAPELLO AS EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER CAMBRIDGE, Mass. November 21, 2017 -- Biogen (Nasdaq: BIIB) announced today the appointment of Jeffrey D. Capello as Executive Vice President and Chief Financial Officer effective as of Decemb
Read more →BIIBBiogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
Read more →BIIBBiogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation
Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation
Read more →BIIBBiogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Read more →BIIBBiogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product
Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product
Read more →BIIBBiogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Read more →BIIBBiogen to Report Third Quarter 2017 Financial Results on October 24, 2017
Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017
Read more →BIIBBiogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab
Read more →BIIBBiogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach
Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach
Read more →BIIBBiogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area
Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area
Read more →BIIBBiogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
Read more →BIIBBiogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
Read more →BIIBBiogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Read more →BIIBIMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union
IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union
Read more →BIIBBiogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences
Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences
Read more →BIIBBiogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance
Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance
Read more →BIIBBiogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017
Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017
Read more →BIIBAlisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations
Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations
Read more →BIIBBiogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)
Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)
Read more →BIIBNew Data Reaffirm Clinically Meaningful Benefit of SPINRAZA® (nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity
New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA® (nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity
Read more →BIIBBiogen Appoints Catherine Steele Senior Vice President of Corporate Affairs
Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs
Read more →BIIBBiogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use
Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use
Read more →BIIBBiogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer
Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer
Read more →BIIBJason Glashow +1 781 464 3260 public.affairs@biogen.com INVESTOR CONTACT: Matt Calistri +1 617 679 3342 IR@biogen.com BIOGEN ANNOUNCES MANAGEMENT CHANGE Cambridge, MA (
BIOGEN ANNOUNCES MANAGEMENT CHANGE Cambridge, MA (June 13, 2017) Biogen (NASDAQ: BIIB) announced today that Paul Clancy, Executive Vice President, Finance & Chief Financial Officer (CFO) will leave the organization to join another biopharmaceutical company. Mr. Clancy will rema
Read more →BIIBBiogen Announces Webcast of Virtual Annual Meeting of Stockholders
Biogen Announces Webcast of Virtual Annual Meeting of Stockholders
Read more →BIIBBiogen’s FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MS
Biogen’s FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MS
Read more →BIIBBiogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference
Biogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference
Read more →BIIBBiogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke
Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke
Read more →BIIBFinal Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
Read more →BIIBBiogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Read more →BIIBBiogen Highlights Advances from Its Neurology Research Programs and Portfolio of Innovative Medicines at AAN Congress
Biogen Highlights Advances from Its Neurology Research Programs and Portfolio of Innovative Medicines at AAN Congress
Read more →BIIBBiogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference
Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference
Read more →BIIBBiogen Completes Separation of Global Hemophilia Business, Bioverativ
Biogen Completes Separation of Global Hemophilia Business, Bioverativ
Read more →BIIBBiogen Fourth Quarter and Year End 2016 Financial Results Webcast Adjusted to 8:00 am on January 26, 2017
Biogen Fourth Quarter and Year End 2016 Financial Results Webcast Adjusted to 8:00 am on January 26, 2017
Read more →BIIBBiogen to Report Fourth Quarter and Year End 2016 Financial Results on January 26, 2017
Biogen to Report Fourth Quarter and Year End 2016 Financial Results on January 26, 2017
Read more →BIIBBiogen Media Contact: Biogen Investor Contact: Jason Glashow Matt Calistri Biogen Inc. Biogen Inc. Tel: (781) 464-3260 Tel: (781) 464-2442 Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement Bi
Biogen Media Contact: Biogen Investor Contact: Jason Glashow Matt Calistri Biogen Inc. Biogen Inc. Tel: (781) 464-3260 Tel: (781) 464-2442 Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement Biogen to Pay $1.25B in Exchange for License Agreement t
Read more →BIIBSiemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis
Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis
Read more →BIIBBiogen and Forward Pharma Agree to Enter into Settlement and License Agreement
Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement
Read more →BIIBNew Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
Read more →BIIBBiogen Announces that Bioverativ will Host an Investor Day on January 6, 2017
Biogen Announces that Bioverativ will Host an Investor Day on January 6, 2017
Read more →BIIBBiogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN(R) half-life extension technology
MOUNTAIN VIEW, CA--(Marketwired - January 05, 2017) - Amunix Operating Inc. announced today that Biogen (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement to develop and commercialize a novel, recombinant Factor IX product candidate th
Read more →BIIBU.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
Read more →BIIBBiogen Announces Effectiveness of Bioverativ Form 10 Registration Statement
Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement
Read more →BIIBBiogen and Spin-off Bioverativ will Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Biogen and Spin-off Bioverativ will Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Read more →BIIBBiogen’s Board of Directors Approves Separation of Bioverativ and Declares Special Dividend Distribution of Bioverativ Stock
Biogen’s Board of Directors Approves Separation of Bioverativ and Declares Special Dividend Distribution of Bioverativ Stock
Read more →BIIBBiogen to Present at the 35th Annual J.P. Morgan Healthcare Conference
Biogen to Present at the 35th Annual J.P. Morgan Healthcare Conference
Read more →BIIBBiogen Names Michel Vounatsos Chief Executive Officer
Biogen Names Michel Vounatsos Chief Executive Officer
Read more →BIIBBiogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting
Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting
Read more →BIIBData Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting
Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting
Read more →BIIBBiogen Announces Additional Members of Management Team of Hemophilia Spin-off Company Bioverativ
Biogen Announces Additional Members of Management Team of Hemophilia Spin-off Company Bioverativ
Read more →BIIBBiogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA
Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA
Read more →BIIBBiogen to Present at the 25th Annual Credit Suisse Healthcare Conference
Biogen to Present at the 25th Annual Credit Suisse Healthcare Conference
Read more →BIIBBiogen to Report Third Quarter 2016 Financial Results on October 26, 2016
Biogen to Report Third Quarter 2016 Financial Results on October 26, 2016
Read more →BIIBNew Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting
New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting
Read more →BIIBBiogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio
Biogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio
Read more →BIIBBiogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation
Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation
Read more →BIIBNature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab
Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab
Read more →BIIBBiogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
Read more →BIIBBiogen Reports Second Quarter 2016 Revenues of $2.9 Billion
Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion
Read more →BIIBBiogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
Read more →BIIBBiogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology
Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology
Read more →BIIBBiogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy
Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy
Read more →BIIBFLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union
Read more →BIIBBiogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
Read more →BIIBBiogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs
Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs
Read more →BIIBAlprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B
Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B
Read more →BIIBBiogen Announces Intent to Spin off Its Hemophilia Business
Biogen Announces Intent to Spin off Its Hemophilia Business
Read more →BIIBAdam Koppel, Executive Vice President, Strategy and Business Development, to Return to Bain Capital
Adam Koppel, Executive Vice President, Strategy and Business Development, to Return to Bain Capital
Read more →BIIBBiogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
Read more →BIIBTECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
Read more →BIIBBiogen Joins in Celebration of World Hemophilia Day
Biogen Joins in Celebration of World Hemophilia Day
Read more →BIIBBiogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
Read more →BIIBFLIXABI®, an Infliximab Biosimilar Candidate Referencing Remicade®, Receives Positive CHMP Opinion
FLIXABI®, an Infliximab Biosimilar Candidate Referencing Remicade®, Receives Positive CHMP Opinion
Read more →BIIBBiogen to Present at the Goldman Sachs Alzheimer’s Symposium
Biogen to Present at the Goldman Sachs Alzheimer’s Symposium
Read more →BIIBBiogen to Present at the Cowen and Company 36th Annual Health Care Conference
Biogen to Present at the Cowen and Company 36th Annual Health Care Conference
Read more →BIIBSobi and Biogen Receive Positive Opinion from CHMP for Alprolix® (rFIXFc) for the Treatment of Hemophilia B
Sobi and Biogen Receive Positive Opinion from CHMP for Alprolix® (rFIXFc) for the Treatment of Hemophilia B
Read more →BIIBBiogen Joins Pioneering Target Validation Collaboration
Biogen Joins Pioneering Target Validation Collaboration
Read more →BIIBBiogen to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Biogen to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Read more →BIIBBiogen to Report Fourth Quarter and Year End 2015 Financial Results on January 27, 2016
Biogen to Report Fourth Quarter and Year End 2015 Financial Results on January 27, 2016
Read more →BIIBBiogen 2015 Revenues Increase 11% to $10.8 Billion
Biogen 2015 Revenues Increase 11% to $10.8 Billion
Read more →BIIBBENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union
BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union
Read more →BIIBBiogen to Present at the 34th Annual J.P. Morgan Healthcare Conference
Biogen to Present at the 34th Annual J.P. Morgan Healthcare Conference
Read more →BIIBNew Data Show ELOCTATE® and ALPROLIX® May Help Control Target Joint Bleeds in People with Hemophilia A and B
New Data Show ELOCTATE® and ALPROLIX® May Help Control Target Joint Bleeds in People with Hemophilia A and B
Read more →BIIBSobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
Sobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
Read more →BIIBBiogen Announces Benepali™ (Etanercept) is the First Biosimilar of Enbrel® to Receive a Positive Opinion from CHMP
Biogen Announces Benepali™ (Etanercept) is the First Biosimilar of Enbrel® to Receive a Positive Opinion from CHMP
Read more →BIIBSteven Holtzman to Retire from Biogen
Steven Holtzman to Retire from Biogen
Read more →BIIBBiogen to Report Third Quarter 2015 Financial Results on October 21, 2015
Biogen to Report Third Quarter 2015 Financial Results on October 21, 2015
Read more →BIIBHemophilia Therapy from Largest Multi-Year Donation Now Available to Patients in Developing World
Hemophilia Therapy from Largest Multi-Year Donation Now Available to Patients in Developing World
Read more →BIIBBiogen Announces Departure of Tony Kingsley
Biogen Announces Departure of Tony Kingsley
Read more →BIIBBIOGEN, INC. SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Against Biogen Inc. -- BIIB
RADNOR, Pa., Oct. 07, 2015 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Biogen Inc. (Nasdaq:BIIB) (“Biogen” or the “Company”) on behalf of purchasers of the Company’s securities bet
Read more →BIIBBiogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, Including New TECFIDERA® Data Demonstrating Importance of Early Treatment
Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, Including New TECFIDERA® Data Demonstrating Importance of Early Treatment
Read more →BIIBBiogen and Sobi Receive Positive Opinion from CHMP for ELOCTA™ (rFVIIIFc) for the Treatment of Hemophilia A
Biogen and Sobi Receive Positive Opinion from CHMP for ELOCTA™ (rFVIIIFc) for the Treatment of Hemophilia A
Read more →BIIBCORRECTING and REPLACING Biogen to Present at Bank of America Merrill Lynch Global Healthcare Conference London
CORRECTING and REPLACING Biogen to Present at Bank of America Merrill Lynch Global Healthcare Conference London
Read more →BIIBBiogen Licenses Mitsubishi Tanabe Pharma’s Phase 2 Molecule for Autoimmune Diseases
Biogen Licenses Mitsubishi Tanabe Pharma’s Phase 2 Molecule for Autoimmune Diseases
Read more →BIIBBiogen to Present at the Morgan Stanley Global Healthcare Conference
Biogen to Present at the Morgan Stanley Global Healthcare Conference
Read more →BIIBUSPTO Dismisses Inter Partes Review Petition of Biogen’s Patent 514 for TECFIDERA® (Dimethyl Fumarate)
USPTO Dismisses Inter Partes Review Petition of Biogen’s Patent 514 for TECFIDERA® (Dimethyl Fumarate)
Read more →BIIBBiogen, the ALS Association and Columbia University Medical Center Collaborate to Drive Understanding of Genetic Influence in ALS
Biogen, the ALS Association and Columbia University Medical Center Collaborate to Drive Understanding of Genetic Influence in ALS
Read more →BIIBResults from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B
Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B
Read more →BIIBExtension Study Data Supporting Long-Term Safety and Efficacy of Eloctate® Published in Haemophilia
Extension Study Data Supporting Long-Term Safety and Efficacy of Eloctate® Published in Haemophilia
Read more →BIIBBiogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015
Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015
Read more →BIIBDouglas Williams to Leave Biogen for Biotechnology Start-Up
Douglas Williams to Leave Biogen for Biotechnology Start-Up
Read more →BIIBBiogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology
Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology
Read more →BIIBBiogen and Sobi announce European Medicines Agency validates Alprolix (rFIXFc) marketing authorisation application
Cambridge, Mass., USA and Stockholm, Sweden, 26 June 2015 Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has accepted the companies' Marketing Authorisation Application (MAA) of Alprolix® (
Read more →BIIBBiogen Achieves Carbon Neutrality
Biogen Achieves Carbon Neutrality
Read more →BIIBBiogen 2015 Annual Shareholder Meeting Webcast
Biogen 2015 Annual Shareholder Meeting Webcast
Read more →BIIBBiogen Names Matt Griffiths as Chief Information Officer
Biogen Names Matt Griffiths as Chief Information Officer
Read more →BIIBBiogen to Present at the 2015 UBS Global Healthcare Conference
Biogen to Present at the 2015 UBS Global Healthcare Conference
Read more →BIIBBiogen Announces $5 Billion Share Repurchase Program
Biogen Announces $5 Billion Share Repurchase Program
Read more →BIIBBiogen to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
Biogen to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
Read more →BIIBBiogen Inc. (Nasdaq: BIIB) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, May 07, 2015 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq:BIIB), one of the world’s oldest independent biotechnology companies, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Paul J. Clancy, Executive Vice President, Finance and Chief Financial
Read more →BIIBBiogen Reports First Quarter 2015 Revenues of $2.6 Billion
Biogen Reports First Quarter 2015 Revenues of $2.6 Billion
Read more →BIIBInternational Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction
International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction
Read more →BIIBTECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
Read more →BIIBBiogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair
Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair
Read more →BIIBEuropean Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS
Read more →BIIBBiogen Idec Becomes Biogen
Biogen Idec Becomes Biogen
Read more →BIIBBiogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix paediatric study
* Study Meets Primary Endpoint and Achieves Low Bleeding Rates with Once- Weekly Prophylactic Dosing in Children * Results Support EU Regulatory Submission and Future Paediatric Indication Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) to
Read more →BIIBBiogen Idec to Present at the Cowen and Company 35th Annual Healthcare Conference
Biogen Idec to Present at the Cowen and Company 35th Annual Healthcare Conference
Read more →BIIBBiogen Idec, Columbia University and HudsonAlpha Institute Identify New ALS Gene and Signaling Pathways
Biogen Idec, Columbia University and HudsonAlpha Institute Identify New ALS Gene and Signaling Pathways
Read more →BIIBBiogenic Reagents Highlights Success of Recently Patented Product
New Bio-Carbon Adopted by More than 50 Municipalities Across North America in 2014 Biogenic Outperforms Legacy Coal-Based Carbons and Continues to Revolutionize Water Purification MINNEAPOLIS, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Biogenic Reagents ("Biogenic"), a leading manufactu
Read more →BIIBBiogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop Gene Therapies for Hemophilia
Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop Gene Therapies for Hemophilia
Read more →BIIBBiogen Idec 2014 Revenues Increase 40% to $9.7 Billion
Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion
Read more →BIIBBiogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 28, 2015
Biogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 28, 2015
Read more →BIIBBiogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research
Biogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research
Read more →BIIBBiogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis
Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis
Read more →BIIBBiogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting
Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting
Read more →BIIBBiogen Idec to Present at the 2014 Deutsche Bank BioFEST Conference
Biogen Idec to Present at the 2014 Deutsche Bank BioFEST Conference
Read more →BIIBBiogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review
Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review
Read more →BIIBLeading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases
Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases
Read more →BIIBBiogen Idec Third Quarter 2014 Revenues Increase 37% to $2.5 Billion
Biogen Idec Third Quarter 2014 Revenues Increase 37% to $2.5 Billion
Read more →BIIBCORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
Read more →BIIBBiogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals
Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals
Read more →BIIBBiogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index
Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index
Read more →BIIBOlivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy
Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy
Read more →BIIBDetailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)
Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)
Read more →BIIBPLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients
PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients
Read more →BIIBNew International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms
Read more →BIIBBiogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care
Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care
Read more →BIIBBiogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014
Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014
Read more →BIIBBiogen Idec in Panel at the Citi 9th Annual Biotech Conference
Biogen Idec in Panel at the Citi 9th Annual Biotech Conference
Read more →BIIBBiogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions
Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions
Read more →BIIBBiogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
Read more →BIIBPLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis
PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis
Read more →BIIBBiogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS)
Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS)
Read more →BIIBBiogenic Reagents and West Fraser Enter Agreement to Develop Renewable Biocarbon Products
MINNEAPOLIS, June 18, 2014 (GLOBE NEWSWIRE) -- Biogenic Reagents, a leading producer of high-value biocarbon products from renewable biomass, announced that it has entered into an agreement with West Fraser, Inc., a U.S. subsidiary of West Fraser Timber (Toronto:WFT), the largest
Read more →BIIBBiogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis
Read more →BIIBData from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses
Data from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses
Read more →BIIBBiogen Idec Announces Official Partnership with Sailing Sclerosis’ “Oceans of Hope” to Globally Change Perceptions of MS
Biogen Idec Announces Official Partnership with Sailing Sclerosis’ “Oceans of Hope” to Globally Change Perceptions of MS
Read more →BIIBBiogenic Reagents Commences Production From Its New Biocarbon Reactor
MINNEAPOLIS, May 28, 2014 (GLOBE NEWSWIRE) -- Biogenic Reagents - the leading producer of high-value carbon products from renewable biomass - today announced that it has initiated commercial production from a new bioreactor at its Marquette, Michigan production facility. The new
Read more →BIIBBiogen Idec to Present at the Sanford Bernstein 30th Annual Strategic Decisions Conference
Biogen Idec to Present at the Sanford Bernstein 30th Annual Strategic Decisions Conference
Read more →BIIBRichard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine
Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine
Read more →BIIBBiogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world
- World Federation of Hemophilia Humanitarian Aid Program to Receive 500 Million International Units Over 5 Years - Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced their intent to produce one billion international units (IU
Read more →BIIBNew TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients
New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients
Read more →BIIBNew Data Reinforce Efficacy of TECFIDERA® (Dimethyl Fumarate) in MS Patients with High Disease Activity
New Data Reinforce Efficacy of TECFIDERA® (Dimethyl Fumarate) in MS Patients with High Disease Activity
Read more →BIIBBiogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting
Biogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting
Read more →BIIBBiogen Idec to Report First Quarter 2014 Financial Results on April 23, 2014
Biogen Idec to Report First Quarter 2014 Financial Results on April 23, 2014
Read more →BIIBBiogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII
MOUNTAIN VIEW, CA--(Marketwired - Apr 21, 2014) - Amunix Operating Inc. announced today that Biogen Idec (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products with impr
Read more →BIIBBiogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting
Read more →BIIBBiogen Idec and Sobi announce positive top-line efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate(TM) (rFVIIIFc) for haemophilia A
- Data showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children under age 12- - Study meets primary objectives; Results enable regulatory submission in EU- Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SO
Read more →BIIBFDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart
FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart
Read more →BIIBHealth Canada Approves Biogen Idec’s Long-Acting ALPROLIX™ Therapy for Hemophilia B
Health Canada Approves Biogen Idec’s Long-Acting ALPROLIX™ Therapy for Hemophilia B
Read more →BIIBEisai and Biogen Idec Enter Collaboration to Develop and Commercialize Alzheimer’s Disease Treatments
Eisai and Biogen Idec Enter Collaboration to Develop and Commercialize Alzheimer’s Disease Treatments
Read more →BIIBTECFIDERA® (Dimethyl Fumarate) Approved in the European Union as a First-Line Oral Treatment for Multiple Sclerosis
TECFIDERA® (Dimethyl Fumarate) Approved in the European Union as a First-Line Oral Treatment for Multiple Sclerosis
Read more →BIIBBiogen Idec 2013 Total Revenues Increase 26 Percent to $6.9 Billion
Biogen Idec 2013 Total Revenues Increase 26 Percent to $6.9 Billion
Read more →BIIBBiogen Idec to Report Fourth Quarter and Year-End 2013 Financial Results on January 29, 2014
Biogen Idec to Report Fourth Quarter and Year-End 2013 Financial Results on January 29, 2014
Read more →BIIBBIOGEN IDEC AND SANGAMO BIOSCIENCES ANNOUNCE GLOBAL COLLABORATION TO DEVELOP TREATMENTS FOR HEMOGLOBINOPATHIES
BIOGEN IDEC AND SANGAMO BIOSCIENCES ANNOUNCE GLOBAL COLLABORATION TO DEVELOP TREATMENTS FOR HEMOGLOBINOPATHIES
Read more →BIIBBiogen Idec to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Biogen Idec to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Read more →BIIBBiogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe
Read more →BIIBBiogen Idec Receives Notification from FDA of PDUFA Date Extension for ALPROLIX™
Biogen Idec Receives Notification from FDA of PDUFA Date Extension for ALPROLIX™
Read more →BIIBBiogen Idec to Present at the 2013 Deutsche Bank BioFEST
Biogen Idec to Present at the 2013 Deutsche Bank BioFEST
Read more →BIIBLeading Hematology Journal Publishes Pivotal ELOCTATE™ Data that Demonstrated Efficacy and Safety of Investigational Long-Lasting Therapy for Hemophilia A
Leading Hematology Journal Publishes Pivotal ELOCTATE™ Data that Demonstrated Efficacy and Safety of Investigational Long-Lasting Therapy for Hemophilia A
Read more →BIIBBiogen Idec to Present at the Credit Suisse Healthcare Conference
Biogen Idec to Present at the Credit Suisse Healthcare Conference
Read more →BIIBBiogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance
Biogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance
Read more →BIIBNew TECFIDERA® (Dimethyl Fumarate) Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients
New TECFIDERA® (Dimethyl Fumarate) Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients
Read more →BIIBNew TYSABRI® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity
New TYSABRI® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity
Read more →BIIBFree Genetic Testing Initiative to be Available Nationally at Hemophilia Treatment Centers
Free Genetic Testing Initiative to be Available Nationally at Hemophilia Treatment Centers
Read more →BIIBNew Data Analyses Show Significant Clinical and MRI Improvements with PLEGRIDY™ (Peginterferon Beta-1a)
New Data Analyses Show Significant Clinical and MRI Improvements with PLEGRIDY™ (Peginterferon Beta-1a)
Read more →BIIBBiogen Idec Becomes First U.S.-Based Biotech Named to Dow Jones Sustainability World Index
Biogen Idec Becomes First U.S.-Based Biotech Named to Dow Jones Sustainability World Index
Read more →BIIBBiogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS
Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS
Read more →BIIBBiogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
Read more →BIIBBiogen Idec Foundation Awards $250,000 Grant to Citizen Schools to Invest in Science Education in Massachusetts and North Carolina
Biogen Idec Foundation Awards $250,000 Grant to Citizen Schools to Invest in Science Education in Massachusetts and North Carolina
Read more →BIIBBiogen Idec to Present at the Stifel Nicolaus 2013 Global Healthcare Conference
Biogen Idec to Present at the Stifel Nicolaus 2013 Global Healthcare Conference
Read more →BIIBBiogen Idec to Present at the Morgan Stanley Global Healthcare Conference
Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference
Read more →BIIBBiogenic Reagents Begins Commercial Production of New Ultra-Adsorptive Graphene-Carbon Compounds From Renewable Sources
MINNEAPOLIS, Aug. 5, 2013 (GLOBE NEWSWIRE) -- Biogenic Reagents ("Biogenic"), a leading manufacturer of high-performance carbon and producer of over a half dozen leading-edge patent-pending carbon technologies, today announced it has begun commercial production of new Ultra-Adsor
Read more →BIIBBiogen Idec to Report Second Quarter 2013 Financial Results on July 25, 2013
Biogen Idec to Report Second Quarter 2013 Financial Results on July 25, 2013
Read more →BIIBBiogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter 2013
Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter 2013
Read more →BIIBBiogen Idec and Sobi Present New Data from the Phase 3 Study of their Long-Lasting Haemophilia Factor Candidate ELOCTATE(TM)
Additional Analyses from Phase 3 A-LONG Study Support Positive Clinical Profile of ELOCTATE for Haemophilia A Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) presented new data that support the clinical and safety profile of their long-las
Read more →BIIBBiogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ALPROLIX™
Biogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ALPROLIX™
Read more →BIIBBiogen Idec 2013 Annual Shareholder Meeting Webcast
Biogen Idec 2013 Annual Shareholder Meeting Webcast
Read more →BIIBBiogen Idec Reinforces Commitment to MS Community on 5th Annual World MS Day
Biogen Idec Reinforces Commitment to MS Community on 5th Annual World MS Day
Read more →BIIBBiogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer
Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer
Read more →BIIBBiogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference
Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference
Read more →BIIBBiogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis
Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis
Read more →BIIBBiogen Idec to Report First Quarter 2013 Financial Results on April 25, 2013
Biogen Idec to Report First Quarter 2013 Financial Results on April 25, 2013
Read more →BIIBUS Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA™ (Dimethyl Fumarate)
US Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA™ (Dimethyl Fumarate)
Read more →BIIBADDING MULTIMEDIA New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status
ADDING MULTIMEDIA New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status
Read more →BIIBBiogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN Annual Meeting
Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN Annual Meeting
Read more →BIIBFDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B
Read more →BIIBBiogen Idec to Present at the 2013 RBC Capital Markets Global Healthcare Conference
Biogen Idec to Present at the 2013 RBC Capital Markets Global Healthcare Conference
Read more →BIIBBiogen Idec to Present at the Citi 2013 Global Healthcare Conference
Biogen Idec to Present at the Citi 2013 Global Healthcare Conference
Read more →BIIBNew Phase 3 Data Reinforce Long-Lasting Protection from Bleeding for Patients with Hemophilia A and B
New Phase 3 Data Reinforce Long-Lasting Protection from Bleeding for Patients with Hemophilia A and B
Read more →BIIBBiogen Idec to Acquire Full Rights and Control of TYSABRI® from Elan for Upfront Cash and Contingent Payments
Biogen Idec to Acquire Full Rights and Control of TYSABRI® from Elan for Upfront Cash and Contingent Payments
Read more →BIIBBiogen Idec 2012 Revenue Increases 9% to $5.5 Billion
Biogen Idec 2012 Revenue Increases 9% to $5.5 Billion
Read more →BIIBBiogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in anti-JCV Antibody Negative Patients with MS
Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in anti-JCV Antibody Negative Patients with MS
Read more →BIIBBiogen Idec Reports Top-Line Results from Phase 3 Trial Investigating Dexpramipexole in People with Amyotrophic Lateral Sclerosis (ALS)
Biogen Idec Reports Top-Line Results from Phase 3 Trial Investigating Dexpramipexole in People with Amyotrophic Lateral Sclerosis (ALS)
Read more →BIIBBiogen Idec to Present at the 31st Annual J.P. Morgan Healthcare Conference
Biogen Idec to Present at the 31st Annual J.P. Morgan Healthcare Conference
Read more →BIIBBiogen Idec Forms First-of-Its-Kind Research Consortium to Identify ALS Drug Targets
Biogen Idec Forms First-of-Its-Kind Research Consortium to Identify ALS Drug Targets
Read more →BIIBBiogen Idec and Eisai Announce Manufacturing Alliance at Research Triangle Park Facilities
Biogen Idec and Eisai Announce Manufacturing Alliance at Research Triangle Park Facilities
Read more →BIIBBiogen Idec Opens New RTP Facility
Biogen Idec Opens New RTP Facility
Read more →BIIBBiogen Idec to Present at the Credit Suisse 2012 Annual Healthcare Conference
Biogen Idec to Present at the Credit Suisse 2012 Annual Healthcare Conference
Read more →BIIBBiogen Idec and Sobi Announce Positive Top-Line Results from Phase 3 Study Investigating Long-Lasting Recombinant Factor VIII Fc Fusion Protein in Hemophilia A
Biogen Idec and Sobi Announce Positive Top-Line Results from Phase 3 Study Investigating Long-Lasting Recombinant Factor VIII Fc Fusion Protein in Hemophilia A
Read more →BIIBBiogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third Quarter
Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third Quarter
Read more →BIIBBiogen Idec Receives Notification of PDUFA Date Extension
Biogen Idec Receives Notification of PDUFA Date Extension
Read more →BIIBNew Data from Phase 3 Studies Provide Additional Evidence Supporting Treatment Effect for Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis
New Data from Phase 3 Studies Provide Additional Evidence Supporting Treatment Effect for Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis
Read more →BIIBTYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MS
TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MS
Read more →BIIBBiogen Idec’s Commitment to MS Demonstrated Through Significant Scientific Data Being Presented at the 28th ECTRIMS
Biogen Idec’s Commitment to MS Demonstrated Through Significant Scientific Data Being Presented at the 28th ECTRIMS
Read more →BIIBBIOGEN IDEC AND SOBI ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING LONG-LASTING RECOMBINANT FACTOR IX FC FUSION PROTEIN IN HEMOPHILIA B
BIOGEN IDEC AND SOBI ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING LONG-LASTING RECOMBINANT FACTOR IX FC FUSION PROTEIN IN HEMOPHILIA B
Read more →BIIBThe New England Journal of Medicine Publishes Pivotal Data Demonstrating Efficacy and Safety of Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis
The New England Journal of Medicine Publishes Pivotal Data Demonstrating Efficacy and Safety of Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis
Read more →BIIBBiogen Idec Employees Participate in 80 Volunteer Projects in 22 Countries as Part of Annual “Care Deeply Volunteer Day”
Biogen Idec Employees Participate in 80 Volunteer Projects in 22 Countries as Part of Annual “Care Deeply Volunteer Day”
Read more →BIIBBiogen Idec Sells BENLYSTA Royalty Rights to DRI Capital Managed Fund
Biogen Idec Sells BENLYSTA Royalty Rights to DRI Capital Managed Fund
Read more →BIIBBiogen Idec to Present at the Stifel Nicolaus Healthcare Conference 2012
Biogen Idec to Present at the Stifel Nicolaus Healthcare Conference 2012
Read more →BIIBCORRECTING and REPLACING Biogen Idec Increases Revenue 18% to $1.4 Billion in the Second Quarter
CORRECTING and REPLACING Biogen Idec Increases Revenue 18% to $1.4 Billion in the Second Quarter
Read more →BIIBBiogen Idec to Report Second Quarter 2012 Financial Results on July 24, 2012
Biogen Idec to Report Second Quarter 2012 Financial Results on July 24, 2012
Read more →BIIBBiogen Idec Announces Collaboration with Leading Research Institutions to Sequence Genomes of Patients with ALS
Biogen Idec Announces Collaboration with Leading Research Institutions to Sequence Genomes of Patients with ALS
Read more →BIIBBiogen Idec and Sobi Initiate Global Clinical Trials of Long-Lasting Hemophilia A and B Product Candidates in Children
Weston, Mass and Stockholm, Sweden - July 5, 2012 - Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum (STO:SOBI) today announced the initiation of two global pediatric clinical trials of the companies' long-lasting recombinant Factor VIII and Factor IX Fc fusion proteins
Read more →BIIBNew AVONEX® Dosing Innovations for People with Multiple Sclerosis Now Available in US
New AVONEX® Dosing Innovations for People with Multiple Sclerosis Now Available in US
Read more →BIIBUS and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review
US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review
Read more →BIIBBiogen Idec to Present at the Deutsche Bank 37th Annual Healthcare Conference
Biogen Idec to Present at the Deutsche Bank 37th Annual Healthcare Conference
Read more →BIIBBiogen Idec Increases Revenue 7% to $1.3 Billion in the First Quarter
Biogen Idec Increases Revenue 7% to $1.3 Billion in the First Quarter
Read more →BIIBBiogen Idec to Report First Quarter 2012 Financial Results on May 1, 2012
Biogen Idec to Report First Quarter 2012 Financial Results on May 1, 2012
Read more →BIIBNew TYSABRI Data Presented at 64th Annual AAN Meeting Highlight Biogen Idec & Elan Commitment to Improving Outcomes in Multiple Sclerosis
New TYSABRI Data Presented at 64th Annual AAN Meeting Highlight Biogen Idec & Elan Commitment to Improving Outcomes in Multiple Sclerosis
Read more →BIIBNew Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s Commitment to Deliver Promising Therapies for Unmet Needs in Neurodegenerative Diseases
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s Commitment to Deliver Promising Therapies for Unmet Needs in Neurodegenerative Diseases
Read more →BIIBBiogen Idec to Present at the Barclays 2012 Global Healthcare Conference
Biogen Idec to Present at the Barclays 2012 Global Healthcare Conference
Read more →BIIBBiogen Idec Submits Application to FDA for Approval of Oral BG-12 to Treat Multiple Sclerosis
Biogen Idec Submits Application to FDA for Approval of Oral BG-12 to Treat Multiple Sclerosis
Read more →BIIBSamsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis
Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis
Read more →BIIBBiogen Idec to Acquire Stromedix
Biogen Idec to Acquire Stromedix
Read more →BIIBBiogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources
Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources
Read more →BIIBASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis
ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis
Read more →BIIBSamsung and Biogen Idec Announce Joint Venture to Develop, Manufacture and Market Biosimilars
Samsung and Biogen Idec Announce Joint Venture to Develop, Manufacture and Market Biosimilars
Read more →BIIBBiogen Idec to Present at the 2011 Deutsche Bank BioFEST
Biogen Idec to Present at the 2011 Deutsche Bank BioFEST
Read more →BIIBBiogen Idec Reports Third Quarter 2011 Results
Biogen Idec Reports Third Quarter 2011 Results
Read more →BIIBBiogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases
Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases
Read more →BIIBBiogen Idec Announces Positive Top-Line Results from Second Phase 3 Trial Investigating Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis
Biogen Idec Announces Positive Top-Line Results from Second Phase 3 Trial Investigating Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis
Read more →BIIBOral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial
Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial
Read more →BIIBBiogen Idec and Elan Receive Notification of PDUFA Date Extension
Biogen Idec and Elan Receive Notification of PDUFA Date Extension
Read more →BIIBData about Early Use and Long-Term Benefit of TYSABRI Presented at 5th Joint Triennial Congress of ECTRIMS and ACTRIMS
Data about Early Use and Long-Term Benefit of TYSABRI Presented at 5th Joint Triennial Congress of ECTRIMS and ACTRIMS
Read more →BIIBData Presented at the 5th Joint Triennial Congress of ECTRIMS and ACTRIMS Demonstrates Biogen Idec’s Novel Science and Commitment to MS Patients
Data Presented at the 5th Joint Triennial Congress of ECTRIMS and ACTRIMS Demonstrates Biogen Idec’s Novel Science and Commitment to MS Patients
Read more →BIIBMore Than 1,000 Biogen Idec Employees across the Globe Help Patients, Communities in First “Care Deeply Volunteer Day”
More Than 1,000 Biogen Idec Employees across the Globe Help Patients, Communities in First “Care Deeply Volunteer Day”
Read more →BIIBBiogen Idec Inc (BIIB) - N 100 - to Ring The NASDAQ Stock Market Opening Bell
ADVISORY, Sept. 16, 2011 (GLOBE NEWSWIRE) -- Biogen Idec [BIIB], the world's oldest independent biotechnology company and a proud member of the NASDAQ-100, will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion, Biogen Idec CFO Paul Clancy wi
Read more →BIIBBiogen Idec to Present at the Stifel Nicolaus 2011 Healthcare Conference
Biogen Idec to Present at the Stifel Nicolaus 2011 Healthcare Conference
Read more →BIIBBiogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis
Read more →BIIBBiogen Idec Strengthens MS ActiveSource® for People with Multiple Sclerosis
Biogen Idec Strengthens MS ActiveSource® for People with Multiple Sclerosis
Read more →BIIBBIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM PRESENT DATA ON LONG-LASTING RECOMBINANT FACTOR VIII THERAPY AT INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS MEETING
- Results Show Potential to Significantly Reduce the Burden of Treatment for People with Hemophilia A. KYOTO, Japan - July 26, 2011 - Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) today announced Phase 1/2a trial data showing that the companies' long-las
Read more →BIIBBiogen Idec to Report Second Quarter 2011 Financial Results on July 26, 2011
Biogen Idec to Report Second Quarter 2011 Financial Results on July 26, 2011
Read more →BIIBBiogen Idec Reports Second Quarter 2011 Results
Biogen Idec Reports Second Quarter 2011 Results
Read more →BIIBBiogen Idec Researchers Identify Novel Approach for Promoting Remyelination and Inhibiting Autoimmune Activation as Potential Therapeutic Option for Treatment of Multiple Sclerosis
Biogen Idec Researchers Identify Novel Approach for Promoting Remyelination and Inhibiting Autoimmune Activation as Potential Therapeutic Option for Treatment of Multiple Sclerosis
Read more →BIIBEuropean Commission Approves Inclusion of Anti-JC Virus Antibody Status as a PML Risk Factor in TYSABRI Labeling
European Commission Approves Inclusion of Anti-JC Virus Antibody Status as a PML Risk Factor in TYSABRI Labeling
Read more →BIIBCORRECTING and REPLACING Biogen Idec Reports Positive Data from AVONEX Dose Titration Study at 2011 Annual Meeting of the Consortium of Multiple Sclerosis Centers
CORRECTING and REPLACING Biogen Idec Reports Positive Data from AVONEX Dose Titration Study at 2011 Annual Meeting of the Consortium of Multiple Sclerosis Centers
Read more →BIIBBiogen Idec to Present at the Jefferies 2011 Global Healthcare Conference
Biogen Idec to Present at the Jefferies 2011 Global Healthcare Conference
Read more →BIIBBiogen Idec to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
Biogen Idec to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
Read more →BIIBBiogen Idec 2011 Annual Shareholder Meeting Webcast
Biogen Idec 2011 Annual Shareholder Meeting Webcast
Read more →BIIB2,700 Students in Greater Boston and North Carolina to Benefit from Biogen Idec Foundation Science Education Grants
2,700 Students in Greater Boston and North Carolina to Benefit from Biogen Idec Foundation Science Education Grants
Read more →BIIBBiogen Idec Celebrates World MS Day
Biogen Idec Celebrates World MS Day
Read more →BIIBBiogen Idec Launches Women in MS Educational Initiative
Biogen Idec Launches Women in MS Educational Initiative
Read more →BIIBEuropean Medicines Agency’s Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorisation Application for FAMPYRA
European Medicines Agency’s Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorisation Application for FAMPYRA
Read more →BIIBBiogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Read more →BIIBBIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM RECEIVE OPINION FROM EMA ON PEDIATRIC PLAN FOR LONG-LASTING HEMOPHILIA B THERAPY
Weston, Mass. and Stockholm, Sweden - May 9, 2011 - Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) today announced that the European Medicines Agency's (EMA) Pediatric Committee (PDCO) has adopted an opinion agreeing to the pediatric investigational plan f
Read more →BIIBBiogen Idec to Present at the Deutsche Bank 36th Annual Healthcare Conference
Biogen Idec to Present at the Deutsche Bank 36th Annual Healthcare Conference
Read more →BIIBCORRECTING and REPLACING Biogen Idec to Report First Quarter 2011 Financial Results on April 21, 2011 Before Market Open, Conference Call at 7:00 am ET
CORRECTING and REPLACING Biogen Idec to Report First Quarter 2011 Financial Results on April 21, 2011 Before Market Open, Conference Call at 7:00 am ET
Read more →BIIBBiogen Idec Reports First Quarter 2011 Results
Biogen Idec Reports First Quarter 2011 Results
Read more →BIIBBiogen Idec Receives Positive Opinion from the CHMP and Authorisation from Health Canada on AVONEX PEN
Biogen Idec Receives Positive Opinion from the CHMP and Authorisation from Health Canada on AVONEX PEN
Read more →BIIBCHMP Recommends Updating TYSABRI Labeling with anti-JC Virus Antibody Status as a Third Factor to Further Stratify Risk of PML
CHMP Recommends Updating TYSABRI Labeling with anti-JC Virus Antibody Status as a Third Factor to Further Stratify Risk of PML
Read more →BIIBBiogen Idec to Present at the Citi 2011 Global Healthcare Conference
Biogen Idec to Present at the Citi 2011 Global Healthcare Conference
Read more →BIIBBiogen Idec to Report Fourth Quarter and Year End 2010 Financial Results on February 1, 2011
Biogen Idec to Report Fourth Quarter and Year End 2010 Financial Results on February 1, 2011
Read more →BIIBBiogen Idec to Present at the 29th Annual J.P. Morgan Healthcare Conference
Biogen Idec to Present at the 29th Annual J.P. Morgan Healthcare Conference
Read more →BIIBBiogen Idec and Elan Submit Applications to Update TYSABRI Labeling That May Help Stratify Risk of PML with Anti-JC Virus Antibody Status
Biogen Idec and Elan Submit Applications to Update TYSABRI Labeling That May Help Stratify Risk of PML with Anti-JC Virus Antibody Status
Read more →BIIBBiogen Idec and Neurimmune Announce Agreement on Three Neurodegenerative Disease Programs
Biogen Idec and Neurimmune Announce Agreement on Three Neurodegenerative Disease Programs
Read more →BIIBAmanda Freitag of Chopped and Iron Chef America Teams up with Multiple Sclerosis Nutritionist to Create Nutrition Resource for People with MS
Amanda Freitag of Chopped and Iron Chef America Teams up with Multiple Sclerosis Nutritionist to Create Nutrition Resource for People with MS
Read more →BIIBBiogen Idec to Present at the 2010 Deutsche Bank BioFEST
Biogen Idec to Present at the 2010 Deutsche Bank BioFEST
Read more →BIIBBiogen Idec Awards Clinical Fellowship Program Grants to Support Education and Research for the Treatment of Multiple Sclerosis
Biogen Idec Awards Clinical Fellowship Program Grants to Support Education and Research for the Treatment of Multiple Sclerosis
Read more →BIIBBiogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Lasting Recombinant Factor VIII Fc Fusion Protein
Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Lasting Recombinant Factor VIII Fc Fusion Protein
Read more →BIIBPhase III Study Showed Rituxan® for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in People with Asymptomatic Follicular Lymphoma, a Common Type of Blood Cancer
Phase III Study Showed Rituxan® for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in People with Asymptomatic Follicular Lymphoma, a Common Type of Blood Cancer
Read more →BIIBBiogen Idec Announces Webcast of Neurodegeneration & Repair R&D Roundtable
Biogen Idec Announces Webcast of Neurodegeneration & Repair R&D Roundtable
Read more →BIIBBiogen Idec to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Biogen Idec to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Read more →BIIBBiogen Idec to Report Third Quarter 2010 Financial Results on October 26, 2010
Biogen Idec to Report Third Quarter 2010 Financial Results on October 26, 2010
Read more →BIIBBiogen Idec Showcases Global, Multiple Sclerosis Leadership with More Than 45 Data Presentations at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Biogen Idec Showcases Global, Multiple Sclerosis Leadership with More Than 45 Data Presentations at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Read more →BIIBBiogen Idec Makes Statement About U.S. FDA Approval of Gilenya™
Biogen Idec Makes Statement About U.S. FDA Approval of Gilenya™
Read more →BIIBBiogen Idec Announces Webcast of Hemophilia R&D Roundtable
Biogen Idec Announces Webcast of Hemophilia R&D Roundtable
Read more →BIIBBiogen Idec to Present at the 2010 UBS Global Life Sciences Conference
Biogen Idec to Present at the 2010 UBS Global Life Sciences Conference
Read more →BIIBBiogen Idec to Present at the Stifel Nicolaus 2010 Healthcare Conference
Biogen Idec to Present at the Stifel Nicolaus 2010 Healthcare Conference
Read more →BIIBBiogen Idec to Present at the 2010 Morgan Stanley Global Healthcare Unplugged Conference
Biogen Idec to Present at the 2010 Morgan Stanley Global Healthcare Unplugged Conference
Read more →BIIBBiogen Idec and Knopp Neurosciences Announce License Agreement for Late-Stage ALS Drug Candidate
Biogen Idec and Knopp Neurosciences Announce License Agreement for Late-Stage ALS Drug Candidate
Read more →BIIBBiogen Idec to Report Second Quarter 2010 Financial Results on July 20, 2010
Biogen Idec to Report Second Quarter 2010 Financial Results on July 20, 2010
Read more →BIIBBiogen Idec and Swedish Orphan Biovitrum Present Data on Long-Lasting Hemophilia B Therapy at the World Federation of Hemophilia Congress
Weston, Mass. and Stockholm, Sweden - July 12, 2010 - Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (STO: SOBI) today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinan
Read more →BIIBBiogen Idec and Swedish Orphan Biovitrum Announce Decision to Advance Long-Lasting Hemophilia A Therapy into a Registrational Trial
Biogen Idec and Swedish Orphan Biovitrum Announce Decision to Advance Long-Lasting Hemophilia A Therapy into a Registrational Trial
Read more →BIIBBiogen Idec Announces Enrollment of First Patient in Phase II BG-12 Combination Trial in Multiple Sclerosis
Biogen Idec Announces Enrollment of First Patient in Phase II BG-12 Combination Trial in Multiple Sclerosis
Read more →BIIBBiogen Idec Provides Update on CEO Search and Management Changes
Biogen Idec Provides Update on CEO Search and Management Changes
Read more →BIIBBiogen Idec 2010 Annual Shareholder Meeting Webcast
Biogen Idec 2010 Annual Shareholder Meeting Webcast
Read more →BIIBBiogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapsing-Remitting Multiple Sclerosis
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapsing-Remitting Multiple Sclerosis
Read more →BIIBBiogen Idec to Present at the 2010 Citi Investment Research Global Healthcare Conference
Biogen Idec to Present at the 2010 Citi Investment Research Global Healthcare Conference
Read more →BIIBBiogen Idec to Present at the Bank of America Merrill Lynch 2010 Healthcare Conference
Biogen Idec to Present at the Bank of America Merrill Lynch 2010 Healthcare Conference
Read more →BIIBBiogen Idec Reports First Quarter 2010 Results TYSABRI® Revenues Increase 32% Year over Year
Biogen Idec Reports First Quarter 2010 Results TYSABRI® Revenues Increase 32% Year over Year
Read more →BIIBBiogen Idec to Report First Quarter 2010 Financial Results on April 20, 2010
Biogen Idec to Report First Quarter 2010 Financial Results on April 20, 2010
Read more →BIIBBiogen Idec Strengthens Position as a Leader in Neurology with 38 Data Presentations at 62nd Annual Meeting of the American Academy of Neurology
Biogen Idec Strengthens Position as a Leader in Neurology with 38 Data Presentations at 62nd Annual Meeting of the American Academy of Neurology
Read more →BIIBBiogen Idec and Elan Enroll First Patient in Large, Well-Controlled Head-to-Head Study of Multiple Sclerosis Treatments
Biogen Idec and Elan Enroll First Patient in Large, Well-Controlled Head-to-Head Study of Multiple Sclerosis Treatments
Read more →BIIBBiogen Idec Appoints Eric Rowinsky and Stephen Sherwin to Board of Directors Pursuant to Agreement with Icahn Partners
Biogen Idec Appoints Eric Rowinsky and Stephen Sherwin to Board of Directors Pursuant to Agreement with Icahn Partners
Read more →BIIBBiogen Idec to Present at the Barclays Capital 2010 Global Healthcare Conference
Biogen Idec to Present at the Barclays Capital 2010 Global Healthcare Conference
Read more →BIIBBiogen Idec to Present at the Cowen and Company 30th Annual Health Care Conference
Biogen Idec to Present at the Cowen and Company 30th Annual Health Care Conference
Read more →BIIBBiogen Idec and Swedish Orphan Biovitrum Update Hemophilia Partnership Agreement
Biogen Idec and Swedish Orphan Biovitrum Update Hemophilia Partnership Agreement
Read more →BIIBFDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
Read more →BIIBBiogen Idec Reports Full Year and Fourth Quarter 2009 Results
Biogen Idec Reports Full Year and Fourth Quarter 2009 Results
Read more →BIIBBiogen Idec to Report Fourth Quarter and Full Year 2009 Financial Results on February 9, 2010
Biogen Idec to Report Fourth Quarter and Full Year 2009 Financial Results on February 9, 2010
Read more →BIIBMultiple Sclerosis Experts Join Biogen Idec’s Research and Development Team
Multiple Sclerosis Experts Join Biogen Idec’s Research and Development Team
Read more →BIIBBiogen Idec Receives Notice of Intention to Nominate Directors at 2010 Meeting of Shareholders
Biogen Idec Receives Notice of Intention to Nominate Directors at 2010 Meeting of Shareholders
Read more →BIIBBiogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Acting Hemophilia B Therapy
Cambridge, Mass. and Stockholm, Sweden - January 25, 2010 - Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: BVT) today announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics
Read more →BIIBBiogen Idec Issues Statement on U.S. Approval of AMPYRA™ (dalfampridine)
Biogen Idec Issues Statement on U.S. Approval of AMPYRA™ (dalfampridine)
Read more →BIIBBiogen Idec Submits Application in Europe for the Approval of Fampridine-PR Tablets to Improve Walking Ability in People with Multiple Sclerosis
Biogen Idec Submits Application in Europe for the Approval of Fampridine-PR Tablets to Improve Walking Ability in People with Multiple Sclerosis
Read more →BIIBWorld-Renowned Yogi Baron Baptiste Unveils New Program to Help People with Multiple Sclerosis
World-Renowned Yogi Baron Baptiste Unveils New Program to Help People with Multiple Sclerosis
Read more →BIIBBiogen Idec Adds Senior Leadership to Commercial and Medical Operations
Biogen Idec Adds Senior Leadership to Commercial and Medical Operations
Read more →BIIBBiogen Idec to Present at the 28th Annual J.P. Morgan Healthcare Conference
Biogen Idec to Present at the 28th Annual J.P. Morgan Healthcare Conference
Read more →BIIBBiogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted 2010: A View from the Top
Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted 2010: A View from the Top
Read more →BIIBBiogen Idec Announces President and Chief Executive Officer James C. Mullen to Retire
Biogen Idec Announces President and Chief Executive Officer James C. Mullen to Retire
Read more →BIIBBiogen Idec Stands Ready to Close Its $17.50 All-Cash Tender Offer for Facet Biotech
Biogen Idec Stands Ready to Close Its $17.50 All-Cash Tender Offer for Facet Biotech
Read more →BIIBBiogen Idec to Present at the 2009 Deutsche Bank Biotech Boston Confab
Biogen Idec to Present at the 2009 Deutsche Bank Biotech Boston Confab
Read more →BIIBBiogen Idec Increases Offer to Acquire Facet Biotech to $17.50 Per Share in Cash; Sends Letter to Facet Biotech Stockholders Describing Its Best-and-Final Offer
Biogen Idec Increases Offer to Acquire Facet Biotech to $17.50 Per Share in Cash; Sends Letter to Facet Biotech Stockholders Describing Its Best-and-Final Offer
Read more →BIIBBiogen Idec to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Biogen Idec to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Read more →BIIBCORRECTING and REPLACING Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference
CORRECTING and REPLACING Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference
Read more →BIIBSubset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn’s Disease
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn’s Disease
Read more →BIIBBiogen Idec to Report Third Quarter 2009 Financial Results on October 20, 2009
Biogen Idec to Report Third Quarter 2009 Financial Results on October 20, 2009
Read more →BIIBBiogen Idec and Biovitrum Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial
Cambridge, Mass and Stockholm, Sweden - October 19, 2009 - Biogen Idec (NASDAQ: BIIB) and Biovitrum AB (STO: BVT) today announced that they plan to advance the companies' long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial
Read more →BIIBElan to Highlight Tysabri Data in Crohn’s Disease at the American College of Gastroenterology Annual Scientific Meeting
Elan to Highlight Tysabri Data in Crohn’s Disease at the American College of Gastroenterology Annual Scientific Meeting
Read more →BIIBBiogen Idec Commences Tender Offer for Facet Biotech
Biogen Idec Commences Tender Offer for Facet Biotech
Read more →BIIBData Supporting Unique Efficacy of TYSABRI Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Data Supporting Unique Efficacy of TYSABRI Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Read more →BIIBBiogen Idec to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Biogen Idec to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Read more →BIIBBiogen Idec Foundation Announces $1 Million Gift to North Carolina Biotechnology Center
Biogen Idec Foundation Announces $1 Million Gift to North Carolina Biotechnology Center
Read more →BIIBBiogen Idec Announces Proposal to Acquire All Outstanding Shares of Facet for $14.50 per Share in Cash
Biogen Idec Announces Proposal to Acquire All Outstanding Shares of Facet for $14.50 per Share in Cash
Read more →BIIBBiogen Idec to Present at the Thomas Weisel Partners Healthcare Conference
Biogen Idec to Present at the Thomas Weisel Partners Healthcare Conference
Read more →BIIBBiogen Idec to Report Second Quarter 2009 Financial Results on July 16, 2009
Biogen Idec to Report Second Quarter 2009 Financial Results on July 16, 2009
Read more →BIIBPhillip A. Sharp to Retire from Biogen Idec Board
Phillip A. Sharp to Retire from Biogen Idec Board
Read more →BIIBBiogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
Read more →BIIBBiogen Idec Announces First Patient Enrolled in the Global Phase III Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis
Biogen Idec Announces First Patient Enrolled in the Global Phase III Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis
Read more →BIIBBiogen Idec Announces Conclusion of Arbitration with Genentech
Biogen Idec Announces Conclusion of Arbitration with Genentech
Read more →BIIBBiogen Idec to Present at the Goldman Sachs 30th Annual Healthcare Conference
Biogen Idec to Present at the Goldman Sachs 30th Annual Healthcare Conference
Read more →BIIBBiogen Idec Announces Preliminary Tabulation of Stockholder Vote by Independent Inspector of Elections
Biogen Idec Announces Preliminary Tabulation of Stockholder Vote by Independent Inspector of Elections
Read more →BIIBSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn’s Disease Patients with Prior Exposure or Inadequate Response to Anti-TNFα Therapy
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn’s Disease Patients with Prior Exposure or Inadequate Response to Anti-TNFα Therapy
Read more →BIIBBiogen Idec Joins with the Global MS Community to Mark World MS Day
Biogen Idec Joins with the Global MS Community to Mark World MS Day
Read more →BIIBBiogen Idec Sends Letter to Stockholders
Biogen Idec Sends Letter to Stockholders
Read more →BIIBBiogen Idec Comments on Proxy Advisory Firms’ Reports
Biogen Idec Comments on Proxy Advisory Firms’ Reports
Read more →BIIBGenentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Read more →BIIBBiogen Idec to Present at the Deutsche Bank 34th Annual Health Care Conference
Biogen Idec to Present at the Deutsche Bank 34th Annual Health Care Conference
Read more →BIIBFirst Ten-Year Follow-Up Shows That Treatment with AVONEX® Leads to Long-Term Benefits in Early Multiple Sclerosis Patients
First Ten-Year Follow-Up Shows That Treatment with AVONEX® Leads to Long-Term Benefits in Early Multiple Sclerosis Patients
Read more →BIIBMRI Data Showing TYSABRI® Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology
MRI Data Showing TYSABRI® Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology
Read more →BIIBBiogen Idec Board Recommends Shareholders Elect Directors with Record of Success in Enhancing the Value of the Company
Biogen Idec Board Recommends Shareholders Elect Directors with Record of Success in Enhancing the Value of the Company
Read more →BIIBBiogen Idec Reports First Quarter 2009 Results
Biogen Idec Reports First Quarter 2009 Results
Read more →BIIBBiogen Idec Showcases Leading Multiple Sclerosis Franchise and Pipeline at the 61st Annual Meeting of the American Academy of Neurology
Biogen Idec Showcases Leading Multiple Sclerosis Franchise and Pipeline at the 61st Annual Meeting of the American Academy of Neurology
Read more →BIIBBiogen Idec to Present at the 4(th) Annual Citi Biotech Day
Biogen Idec to Present at the 4(th) Annual Citi Biotech Day
Read more →BIIBBiogen Idec Highlights Progress and Breadth of Pipeline Programs at R&D Day
Biogen Idec Highlights Progress and Breadth of Pipeline Programs at R&D Day
Read more →BIIBBiogen Idec Announces March 25 Webcast of Research & Development Day
Biogen Idec Announces March 25 Webcast of Research & Development Day
Read more →BIIBPhase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Read more →BIIBBiogen Idec to Present at the Cowen & Company 29th Annual Healthcare Conference
Biogen Idec to Present at the Cowen & Company 29th Annual Healthcare Conference
Read more →BIIBBiogen Idec Names Michael Lytton Executive Vice President of Business Development
Biogen Idec Names Michael Lytton Executive Vice President of Business Development
Read more →BIIBBiogen Idec Receives Shareholder Proposal
Biogen Idec Receives Shareholder Proposal
Read more →BIIBBiogen Idec Reports Full Year and Fourth Quarter 2008 Results
Biogen Idec Reports Full Year and Fourth Quarter 2008 Results
Read more →BIIBBiogen Idec to Report Fourth Quarter and Full Year 2008 Financial Results on February 6, 2009
Biogen Idec to Report Fourth Quarter and Full Year 2008 Financial Results on February 6, 2009
Read more →BIIBBiogen Idec to Present at the 27th Annual J.P. Morgan Healthcare Conference
Biogen Idec to Present at the 27th Annual J.P. Morgan Healthcare Conference
Read more →BIIBRituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Read more →BIIBBiogen Idec to Present at the Credit Suisse 2008 Healthcare Conference
Biogen Idec to Present at the Credit Suisse 2008 Healthcare Conference
Read more →BIIBBiogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule
Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule
Read more →BIIBPhase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis
Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis
Read more →BIIBBiogen Idec to Report Third Quarter 2008 Financial Results on October 21, 2008
Biogen Idec to Report Third Quarter 2008 Financial Results on October 21, 2008
Read more →BIIBBiogen Idec Reports Third Quarter 2008 Results
Biogen Idec Reports Third Quarter 2008 Results
Read more →BIIBBiogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis
Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis
Read more →BIIBPhase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
Read more →BIIBBiogen Idec Features Data on AVONEX(R) and TYSABRI(R) and Showcases the Company's Multiple Sclerosis Development Pipeline at the World Congress On Treatment and Research in Multiple Sclerosis
Biogen Idec Features Data on AVONEX(R) and TYSABRI(R) and Showcases the Company's Multiple Sclerosis Development Pipeline at the World Congress On Treatment and Research in Multiple Sclerosis
Read more →BIIBNew Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
Read more →BIIBElan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Read more →BIIBBiogen Idec to Present at the 3rd Annual CITI Biotech Day
Biogen Idec to Present at the 3rd Annual CITI Biotech Day
Read more →BIIBBiogen Idec Initiates Phase III Clinical Trial for ADENTRI(R) in Acute Decompensated Heart Failure Patients with Renal Insufficiency
Biogen Idec Initiates Phase III Clinical Trial for ADENTRI(R) in Acute Decompensated Heart Failure Patients with Renal Insufficiency
Read more →BIIBBiogen Idec and Elan Will Host a Conference Call For the Investment Community
Biogen Idec and Elan Will Host a Conference Call For the Investment Community
Read more →BIIBBiogen Idec Reports Second Quarter 2008 Results
Biogen Idec Reports Second Quarter 2008 Results
Read more →BIIBBiogen Idec to Report Second Quarter 2008 Financial Results on July 22, 2008
Biogen Idec to Report Second Quarter 2008 Financial Results on July 22, 2008
Read more →BIIBBiogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Read more →BIIBBiogen Idec Announces Certified Stockholder Vote Results, Confirming Election of All Four of the Board's Director Nominees
Biogen Idec Announces Certified Stockholder Vote Results, Confirming Election of All Four of the Board's Director Nominees
Read more →BIIBBiogen Idec Stockholders Elect Company's Board Nominees
Biogen Idec Stockholders Elect Company's Board Nominees
Read more →BIIBProxy Governance Endorses All Four Biogen Idec Director Nominees
Proxy Governance Endorses All Four Biogen Idec Director Nominees
Read more →BIIBRiskMetrics and Glass Lewis Endorse All Four Biogen Idec Director Nominees
RiskMetrics and Glass Lewis Endorse All Four Biogen Idec Director Nominees
Read more →BIIBBiogen Idec Names Hans Peter Hasler Chief Operating Officer
Biogen Idec Names Hans Peter Hasler Chief Operating Officer
Read more →BIIBBiogen Idec Celebrates 30 Years of Transforming Discovery into Care
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
Read more →BIIBBiogen Idec Commences Mailing of Proxy Materials to Shareholders
Biogen Idec Commences Mailing of Proxy Materials to Shareholders
Read more →BIIBGenentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Read more →BIIBBiogen Idec Reports First Quarter 2008 Results
Biogen Idec Reports First Quarter 2008 Results
Read more →BIIBBiogen Idec to Report First Quarter 2008 Financial Results on April 23, 2008
Biogen Idec to Report First Quarter 2008 Financial Results on April 23, 2008
Read more →BIIBBiogen Idec Announces Slate of Directors for Annual Meeting of Shareholders
Biogen Idec Announces Slate of Directors for Annual Meeting of Shareholders
Read more →BIIBBiogen Idec Announces Multiple Sclerosis Franchise and Pipeline Presentations at the 60th Annual Meeting of the American Academy of Neurology
Biogen Idec Announces Multiple Sclerosis Franchise and Pipeline Presentations at the 60th Annual Meeting of the American Academy of Neurology
Read more →BIIBBiogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
Read more →BIIBGenentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
Read more →BIIBResearchers Report Neublastin Virtually Restores Complete Long-Term Sensory Motor Function in Preclinical Studies
Researchers Report Neublastin Virtually Restores Complete Long-Term Sensory Motor Function in Preclinical Studies
Read more →BIIBBiogen Idec Prices $1.0 Billion Senior Unsecured Notes Offering
Biogen Idec Prices $1.0 Billion Senior Unsecured Notes Offering
Read more →BIIBBiogen Idec and Cardiokine Initiate Phase III Clinical Trial for Lixivaptan in Congestive Heart Failure Patients with Hyponatremia
Biogen Idec and Cardiokine Initiate Phase III Clinical Trial for Lixivaptan in Congestive Heart Failure Patients with Hyponatremia
Read more →BIIBBiogen Idec Reports Full Year and Fourth Quarter 2007 Results
Biogen Idec Reports Full Year and Fourth Quarter 2007 Results
Read more →BIIBBiogen Idec to Report Fourth Quarter and Full Year 2007 Financial Results on February 6, 2008
Biogen Idec to Report Fourth Quarter and Full Year 2007 Financial Results on February 6, 2008
Read more →BIIBBiogen Idec Announces Webcast of Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Biogen Idec Announces Webcast of Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Read more →BIIBBiogen Idec Receives Director Nomination Proposal
Biogen Idec Receives Director Nomination Proposal
Read more →BIIBBiogen Idec to Present at the Wachovia 2008 Healthcare Conference
Biogen Idec to Present at the Wachovia 2008 Healthcare Conference
Read more →BIIBFDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
Read more →BIIBBiogen Idec Announces Appointment of Nancy L. Leaming to Board of Directors
Biogen Idec Announces Appointment of Nancy L. Leaming to Board of Directors
Read more →BIIBBiogen Idec Provides Business Update at Investor Meeting
Biogen Idec Provides Business Update at Investor Meeting
Read more →BIIBBiogen Idec and Vernalis Plc Announce the Start of Phase II Program of BIIB014 in Parkinson's Disease
CAMBRIDGE, Mass. and WINNERSH, U.K., May 8, 2007 (PRIME NEWSWIRE) -- Biogen Idec (Nasdaq:BIIB) and Vernalis plc (Nasdaq:VNLS) (LSE:VER) today announced the initiation of the Phase II program of BIIB014 (also known as V2006), an oral compound, for the treatment of Parkinson's dise
Read more →Competitive Position
How BIIB ranks across every disease it competes inCompetitive Position is a premium feature
See how BIIB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial